Author: "Stéphane Derrey" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Stéphane Derrey"' showing total 139 results

Start Over Author "Stéphane Derrey"

139 results on '"Stéphane Derrey"'

1. Role of gastric motility in weight gain after subthalamic nucleus stimulation in Parkinson's disease

Author: Nathalie Chastan, Najate Achamrah, Stéphane Derrey, David Maltete, Moise Coeffier, Anne-Marie Leroi, Pierre Dechelotte, Marie-Laure Welter, and Guillaume Gourcerol
Subjects: Parkinson's disease, Deep brain stimulation, Subthalamic nucleus, Weight gain, Gastric motility, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Published: 2021
Full Text: View/download PDF

2. Patient Selection in a Pragmatic Study on the Management of Patients with Brain Arteriovenous Malformations

Author: Jean Raymond, Anass Benomar, Jean-Christophe Gentric, Elsa Magro, Lorena Nico, Emma Bacchus, Ruby Klink, Daniela Iancu, Alain Weill, Daniel Roy, Michel W. Bojanowski, Chiraz Chaalala, Omer Eker, Isabelle Pelissou-Guyotat, Michel Piotin, Sorin Aldea, Charlotte Barbier, Thomas Gaberel, Chrysanthi Papagiannaki, Stéphane Derrey, Thanh N. Nguyen, Mohamad Abdalkader, Christophe Cognard, Anne-Christine Januel, Jean-François Sabatier, Vincent Jecko, Xavier Barreau, Vincent Costalat, Marine Le Corre, Jean-Yves Gauvrit, Xavier Morandi, Alessandra Biondi, Laurent Thines, Hubert Desal, Romain Bourcier, Rémy Beaujeux, François Proust, Geraldine Viard, Guylaine Gevry, Tim E. Darsaut, Cian J. O'Kelly, Michael MC. Chow, J. Max Findlay, Jeremy L. Rempel, Robert Fahed, Howard Lesiuk, Brian Drake, Marlene dos Santos, Michel Nonent, Julien Ognard, Mourad Cheddad El-Aouni, Romuald Seizeur, Serge Timsit, Olivier Pradier, Romain Boursier, François Thillays, Vincent Roualdes, Raphael Blanc, Lionel Calviere, Jean Yves Gauvrit, Hélène Raoult, François Eugene, Anthony Le Bras, Jean-Christophe Ferre, Christophe Paya, Isabelle Lecouillard, Elodie Nouhaud, Thomas Ronziere, Denis Trystram, Olivier Naggara, Christine Rodriguez-Regent, Basile Kerleroux, Evelyne Emery, Emmanuel Touze, Roberto Riva, Isabelle Pellisou-Guyotat, Jacques Guyotat, Monsef Berhouma, Chloé Dumot, Nassim Bougaci, Guillaume Charbonnier, Serge Bracard, René Anxionnat, Benjamin Gory, Thierry Civit, Valérie Bernier-Chastagner, Gaultier Marnat, Guillaume Penchet, Edouard Gimbert, Aymeri Huchet, Denis Herbreteau, Grégoire Boulouis, Richard Bibi, Héloïse Ifergan, Kévin Janot, Stéphane Velut, Hervé Brunel, Pierre-Hugues Roche, Thomas Graillon, Hadrien Peyriere, Jean-Marc Kaya, Adamou Touta, Lucas Troude, Sébastien Boissonneau, Frédéric Clarençon, Eimad Shotar, Nader Sourour, Stéphanie Lenck, Kévin Premat, Anne-Laure Boch, Philippe Cornu, Aurélien Nouet, Alain Bonafe, Cyril Dargazanli, Gregory Gascou, Pierre-Henri Lefevre, Carlos Riquelme, Raoul Pop, Hélène Cebula, Irène Ollivier, Giorgio Spatola, Laurent Spell, Vanessa Chalumeau, Sophie Gallas, Léon Ikka, Cristian Mihalea, Augustin Ozanne, Jildaz Caroff, Emmanuel Chabert, Charbel Mounayer, Aymeric Rouchaud, François Caire, Frédéric Ricolfi, Pierre Thouant, Catherine Cao, Klaus-Luc Mourier, Walid Farah, Thien Huynh, Rabih G. Tawk, Andrew P. Carlson, Luciana Alves Oliveira Silva, Nayara de Lima Froio, Gisele Sampaio Silva, Francisco J.A. Mont’Alverne, Jose Luri Martins, George Nunes Mendes, and Rodrigo Rivera Miranda
Subjects: Surgery, Neurology (clinical)
Published: 2023
Full Text: View/download PDF

3. Microsurgical Clipping of Middle Cerebral Artery Aneurysms: Complications and Risk Factors for Complications

Author: Denis Vivien, Thomas Gaberel, Arthur Leclerc, Stéphane Derrey, Sorin Aldea, Olivier Langlois, Evelyne Emery, Alin Borha, Thomas Metayer, Caroline Le Guerinel, Charlotte Barbier, Michel Piotin, and Anaïs R Briant
Subjects: medicine.medical_specialty, Microsurgery, Hematoma, Middle Cerebral Artery, business.industry, Endovascular Procedures, Intracranial Aneurysm, Aneurysm, Ruptured, Surgery, Brain Ischemia, Microsurgical clipping, Treatment Outcome, Risk Factors, medicine.artery, Middle cerebral artery, medicine, Humans, Neurology (clinical), business, Retrospective Studies
Abstract: Objective Middle cerebral artery aneurysms (MCAas) with rupture and unruptured IAs are considered good candidates for microsurgery. The objective of the present study was to evaluate the risk of complications and the risk factors for microsurgical treatment of MCAas to better define the indications for microsurgery. Methods We conducted a retrospective cohort study based on data provided from three French tertiary neurosurgical units from January 1, 2013 to May 31, 2020. We first collected data on all the patients who required microsurgical treatment for MCAas. We evaluated the frequency of complications and finally searched for the risk factors for complications after microsurgery. Complications were defined as a composite criterion with the presence of one of the following: procedural-related death, symptomatic cerebral ischemia, impossible exclusion, incomplete exclusion, or (re)bleeding of the treated aneurysm and symptomatic surgical site hematoma. We then compared patients with and without complications using univariate and multivariate analyses. Results Between January 2013 and May 2020, 292 MCAas in 284 patients were treated. A total of 29 (9.9%) MCAas had a complication. The complications were as follows: symptomatic cerebral ischemia: 4.8%, aneurysm rebleeding: 0.3%, surgical site hematoma: 1.0%, impossible exclusion: 0.3%, and incomplete exclusion: 4.1%. However, severe complications, defined as death or a modified Rankin score (mRs) score ≥4 at 3 months, were infrequent and occurred in 7/292 patients (2.4%). In the multivariate analysis, independent risk factors for complications were the following: a ruptured aneurysm, a larger maximum IA size, a larger neck size, and arterial branches passing less than
Published: 2022
Full Text: View/download PDF

4. Endovascular treatment of brain arteriovenous malformations: clinical outcomes of patients included in the registry of a pragmatic randomized trial

Author: Jean Raymond, Jean-Christophe Gentric, Elsa Magro, Lorena Nico, Emma Bacchus, Ruby Klink, Christophe Cognard, Anne-Christine Januel, Jean-François Sabatier, Daniela Iancu, Alain Weill, Daniel Roy, Michel W. Bojanowski, Chiraz Chaalala, Xavier Barreau, Vincent Jecko, Chrysanthi Papagiannaki, Stéphane Derrey, Eimad Shotar, Philippe Cornu, Omer F. Eker, Isabelle Pelissou-Guyotat, Michel Piotin, Sorin Aldea, Rémy Beaujeux, François Proust, René Anxionnat, Vincent Costalat, Marine Le Corre, Jean-Yves Gauvrit, Xavier Morandi, Hervé Brunel, Pierre-Hugues Roche, Thomas Graillon, Emmanuel Chabert, Denis Herbreteau, Hubert Desal, Denis Trystram, Charlotte Barbier, Thomas Gaberel, Thanh N. Nguyen, Geraldine Viard, Guylaine Gevry, Tim E. Darsaut, Cian J. O’Kelly, Michael M. C. Chow, J. Max Findlay, Jeremy L. Rempel, Robert Fahed, Howard Lesiuk, Brian Drake, Marlene dos Santos, Michel Nonent, Julien Ognard, Mourad Cheddad El-Aouni, Romuald Seizeur, Serge Timsit, Olivier Pradier, Romain Boursier, François Thillays, Vincent Roualdes, Raphael Blanc, Lionel Calviere, Jean Yves Gauvrit, Hélène Raoult, François Eugene, Anthony Le Bras, Jean-Christophe Ferre, Christophe Paya, Isabelle Lecouillard, Elodie Nouhaud, Thomas Ronziere, Olivier Naggara, Christine Rodriguez-Regent, Basile Kerleroux, Evelyne Emery, Emmanuel Touze, Roberto Riva, Isabelle Pellisou-Guyotat, Jacques Guyotat, Monsef Berhouma, Chloé Dumot, Alessandra Biondi, Laurent Thines, Nassim Bougaci, Guillaume Charbonnier, Serge Bracard, Benjamin Gory, Thierry Civit, Valérie Bernier-Chastagner, Gaultier Marnat, Guillaume Penchet, Edouard Gimbert, Aymeri Huchet, Grégoire Boulouis, Richard Bibi, Héloïse Ifergan, Kévin Janot, Stéphane Velut, Hadrien Peyriere, Jean-Marc Kaya, Adamou Touta, Lucas Troude, Sébastien Boissonneau, Frédéric Clarençon, Nader Sourour, Stéphanie Lenck, Kévin Premat, Anne-Laure Boch, Aurélien Nouet, Alain Bonafe, Cyril Dargazanli, Gregory Gascou, Pierre-Henri Lefevre, Carlos Riquelme, Raoul Pop, Hélène Cebula, Irène Ollivier, Giorgio Spatola, Laurent Spell, Vanessa Chalumeau, Sophie Gallas, Léon Ikka, Cristian Mihalea, Augustin Ozanne, Jildaz Caroff, Charbel Mounayer, Aymeric Rouchaud, François Caire, Frédéric Ricolfi, Pierre Thouant, Catherine Cao, Klaus-Luc Mourier, Walid Farah, Mohamad Abdalkader, Thien Huynh, Rabih G. Tawk, Andrew P. Carlson, Luciana Alves Oliveira Silva, Nayara de Lima Froio, Gisele Sampaio Silva, Francisco J. A. Mont’Alverne, Jose Luri Martins, George Nunes Mendes, and Rodrigo Rivera Miranda
Subjects: General Medicine
Abstract: OBJECTIVE The role of endovascular treatment in the management of patients with brain arteriovenous malformations (AVMs) remains uncertain. AVM embolization can be offered as stand-alone curative therapy or prior to surgery or stereotactic radiosurgery (SRS) (pre-embolization). The Treatment of Brain AVMs Study (TOBAS) is an all-inclusive pragmatic study that comprises two randomized trials and multiple registries. METHODS Results from the TOBAS curative and pre-embolization registries are reported. The primary outcome for this report is death or dependency (modified Rankin Scale [mRS] score > 2) at last follow-up. Secondary outcomes include angiographic results, perioperative serious adverse events (SAEs), and permanent treatment-related complications leading to an mRS score > 2. RESULTS From June 2014 to May 2021, 1010 patients were recruited in TOBAS. Embolization was chosen as the primary curative treatment for 116 patients and pre-embolization prior to surgery or SRS for 92 patients. Clinical and angiographic outcomes were available in 106 (91%) of 116 and 77 (84%) of 92 patients, respectively. In the curative embolization registry, 70% of AVMs were ruptured, and 62% were low-grade AVMs (Spetzler-Martin grade I or II), while the pre-embolization registry had 70% ruptured AVMs and 58% low-grade AVMs. The primary outcome of death or disability (mRS score > 2) occurred in 15 (14%, 95% CI 8%–22%) of the 106 patients in the curative embolization registry (4 [12%, 95% CI 5%–28%] of 32 unruptured AVMs and 11 [15%, 95% CI 8%–25%] of 74 ruptured AVMs) and 9 (12%, 95% CI 6%–21%) of the 77 patients in the pre-embolization registry (4 [17%, 95% CI 7%–37%] of 23 unruptured AVMs and 5 [9%, 95% CI 4%–20%] of 54 ruptured AVMs) at 2 years. Embolization alone was confirmed to occlude the AVM in 32 (30%, 95% CI 21%–40%) of the 106 curative attempts and in 9 (12%, 95% CI 6%–21%) of 77 patients in the pre-embolization registry. SAEs occurred in 28 of the 106 attempted curative patients (26%, 95% CI 18%–35%, including 21 new symptomatic hemorrhages [20%, 95% CI 13%–29%]). Five of the new hemorrhages were in previously unruptured AVMs (n = 32; 16%, 95% CI 5%–33%). Of the 77 pre-embolization patients, 18 had SAEs (23%, 95% CI 15%–34%), including 12 new symptomatic hemorrhages [16%, 95% CI 9%–26%]). Three of the hemorrhages were in previously unruptured AVMs (3/23; 13%, 95% CI 3%–34%). CONCLUSIONS Embolization as a curative treatment for brain AVMs was often incomplete. Hemorrhagic complications were frequent, even when the specified intent was pre-embolization before surgery or SRS. Because the role of endovascular treatment remains uncertain, it should preferably, when possible, be offered in the context of a randomized trial.
Published: 2022
Full Text: View/download PDF

5. Surgical treatment of brain arteriovenous malformations: clinical outcomes of patients included in the registry of a pragmatic randomized trial

Author: Tim E. Darsaut, Elsa Magro, Michel W. Bojanowski, Chiraz Chaalala, Lorena Nico, Emma Bacchus, Ruby Klink, Daniela Iancu, Alain Weill, Daniel Roy, Jean-Francois Sabatier, Christophe Cognard, Anne-Christine Januel, Isabelle Pelissou-Guyotat, Omer Eker, Pierre-Hugues Roche, Thomas Graillon, Hervé Brunel, Francois Proust, Rémy Beaujeux, Sorin Aldea, Michel Piotin, Philippe Cornu, Eimad Shotar, Thomas Gaberel, Charlotte Barbier, Marine Le Corre, Vincent Costalat, Vincent Jecko, Xavier Barreau, Xavier Morandi, Jean-Yves Gauvrit, Stéphane Derrey, Chrysanthi Papagiannaki, Thanh N. Nguyen, Mohamad Abdalkader, Rabih G. Tawk, Thien Huynh, Geraldine Viard, Guylaine Gevry, Jean-Christophe Gentric, Jean Raymond, Jeremy L. Rempel, Cian J. O’Kelly, Michael M. C. Chow, J. Max Findlay, Robert Fahed, Howard Lesiuk, Brian Drake, Marlene dos Santos, Romuald Seizeur, Michel Nonent, Serge Timsit, Olivier Pradier, Julien Ognard, Mourad Cheddad El-Aouni, Hubert Desal, Romain Boursier, François Thillays, Vincent Roualdes, Raphael Blanc, Jean-François Sabatier, Lionel Calviere, Jean Yves Gauvrit, Isabelle Lecouillard, Elodie Nouhaud, Hélène Raoult, François Eugene, Anthony Le Bras, Jean-Christophe Ferre, Christophe Paya, Thomas Ronziere, Denis Trystram, Olivier Naggara, Christine Rodriguez-Regent, Basile Kerleroux, Evelyne Emery, Emmanuel Touze, Stephane Derrey, Isabelle Pellisou-Guyotat, Jacques Guyotat, Monsef Berhouma, Roberto Riva, Chloé Dumot, Alessandra Biondi, Laurent Thines, Guillaume Charbonnier, Nassim Bougaci, Serge Bracard, René Anxionnat, Valérie Bernier-Chastagner, Thierry Civit, Benjamin Gory, Guillaume Penchet, Edouard Gimbert, Gaulthier Marnat, Aymeri Huchet, Denis Herbreteau, Grégoire Boulouis, Stéphane Velut, Richard Bibi, Héloïse Ifergan, Kévin Janot, Hadrien Peyriere, Jean-Marc Kaya, Adamou Touta, Lucas Troude, Sébastien Boissonneau, Anne-Laure Boch, Frédéric Clarençon, Nader Sourour, Aurélien Nouet, Stéphanie Lenck, Kévin Premat, Alain Bonafe, Cyril Dargazanli, Gregory Gascou, Pierre-Henri Lefevre, Carlos Riquelme, Hélène Cebula, Irène Ollivier, Raoul Pop, Giorgio Spatola, Laurent Spelle, Vanessa Chalumeau, Sophie Gallas, Léon Ikka, Cristian Mihalea, Augustin Ozanne, Jildaz Caroff, Emmanuel Chabert, Charbel Mounayer, Aymeric Rouchaud, Francois Caire, Frédéric Ricolfi, Catherine Cao, Klaus-Luc Mourier, Pierre Thouant, Walid Farah, Andrew P. Carlson, Luciana Alves Oliveira Silva, Nayara de Lima Froio, Gisele Sampaio Silva, Francisco J. A. Mont’Alverne, Jose Luri Martins, George Nunes Mendes, and Rodrigo Rivera Miranda
Subjects: General Medicine
Abstract: OBJECTIVE The Treatment of Brain Arteriovenous Malformations Study (TOBAS) is a pragmatic study that includes 2 randomized trials and registries of treated or conservatively managed patients. The authors report the results of the surgical registry. METHODS TOBAS patients are managed according to an algorithm that combines clinical judgment and randomized allocation. For patients considered for curative treatment, clinicians selected from surgery, endovascular therapy, or radiation therapy as the primary curative method, and whether observation was a reasonable alternative. When surgery was selected and observation was deemed unreasonable, the patient was not included in the randomized controlled trial but placed in the surgical registry. The primary outcome of the trial was mRS score > 2 at 10 years (at last follow-up for the current report). Secondary outcomes include angiographic results, perioperative serious adverse events, and permanent treatment-related complications leading to mRS score > 2. RESULTS From June 2014 to May 2021, 1010 patients were recruited at 30 TOBAS centers. Surgery was selected for 229/512 patients (44%) considered for curative treatment; 77 (34%) were included in the surgery versus observation randomized trial and 152 (66%) were placed in the surgical registry. Surgical registry patients had 124/152 (82%) ruptured and 28/152 (18%) unruptured arteriovenous malformations (AVMs), with the majority categorized as low-grade Spetzler-Martin grade I–II AVM (118/152 [78%]). Thirteen patients were excluded, leaving 139 patients for analysis. Embolization was performed prior to surgery in 78/139 (56%) patients. Surgical angiographic cure was obtained in 123/139 all-grade (89%, 95% CI 82%–93%) and 105/110 low-grade (95%, 95% CI 90%–98%) AVM patients. At the mean follow-up of 18.1 months, 16 patients (12%, 95% CI 7%–18%) had reached the primary safety outcome of mRS score > 2, including 11/16 who had a baseline mRS score ≥ 3 due to previous AVM rupture. Serious adverse events occurred in 29 patients (21%, 95% CI 15%–28%). Permanent treatment-related complications leading to mRS score > 2 occurred in 6/139 patients (4%, 95% CI 2%–9%), 5 (83%) of whom had complications due to preoperative embolization. CONCLUSIONS The surgical treatment of brain AVMs in the TOBAS registry was curative in 88% of patients. The participation of more patients, surgeons, and centers in randomized trials is needed to definitively establish the role of surgery in the treatment of unruptured brain AVMs. Clinical trial registration no.: NCT02098252 (ClinicalTrials.gov)
Published: 2022
Full Text: View/download PDF

6. Massive non-aneurysmal subarachnoid hemorrhage after cervical carotid angioplasty and stenting: A case report and review of the literature

Author: Alice Goia, S. Curey, Arthur Leclerc, Stéphane Derrey, and V. Gilard
Subjects: Male, medicine.medical_specialty, Subarachnoid hemorrhage, medicine.medical_treatment, Hematoma, Carotid angioplasty, Angioplasty, Carotid artery disease, medicine, Humans, Carotid Stenosis, cardiovascular diseases, Aged, business.industry, Syndrome, Subarachnoid Hemorrhage, medicine.disease, Surgery, Carotid Arteries, Stents, Neurology (clinical), Presentation (obstetrics), Carotid stenting, business, Intracranial Hemorrhages, Carotid Artery, Internal, External ventricular drain
Abstract: Introduction Carotid angioplasty and stenting (CAS) of the cervical segment is a safe and effective procedure for the treatment of carotid artery disease. In rare cases, this procedure causes intracranial hemorrhage (ICH), which is described most often as an ipsilateral intra-parenchymal hematoma. This ICH is the result of a cerebral hyperperfusion syndrome (CHS). Isolated subarachnoid hemorrhage may occur exceptionally, with only 9 cases that have been reported in the literature. Observation We reported a case of a 71-year-old man who presented a massive non-aneurysmal subarachnoid hemorrhage one hour after angioplasty and stenting of the cervical segment of the left internal carotid artery. Medical and surgical management included external ventricular drain placement. Rebleeding occurred two days later, worsening the patient's clinical condition. Finally, the patient died 2 weeks later. Comments This rare presentation of ICH following CAS allows us to discuss the risk factors, complications and management of CHS.
Published: 2022
Full Text: View/download PDF

7. Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study

Author: Marine Lottin, Alexandre Escande, Luc Bauchet, Marie Albert-Thananayagam, Maël Barthoulot, Matthieu Peyre, Mathieu Boone, Sonia Zouaoui, Jacques Guyotat, Guillaume Penchet, Johan Pallud, Henry Dufour, Evelyne Emery, Michel Lefranc, Sébastien Freppel, Houman Namaki, Edouard Gueye, Jean-Jacques Lemaire, Bertrand Muckensturm, Robin Srour, Stéphane Derrey, Apolline Monfilliette, Jean-Marc Constans, Claude-Alain Maurage, Bruno Chauffert, Nicolas Penel, CHU Amiens-Picardie, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Faculté de Médecine Henri Warembourg - Université de Lille, Centre de Recherche en Informatique, Signal et Automatique de Lille - UMR 9189 (CRIStAL), Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Neurochirurgie [Hôpital Gui de Chauliac], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Registre des Tumeurs de l'Hérault, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 (CHIMERE), Université de Picardie Jules Verne (UPJV), Hospices Civils de Lyon (HCL), CHU Bordeaux [Bordeaux], Hôpital d'Instruction des Armées Sainte Anne, Service de Santé des Armées, Hôpital de la Timone [CHU - APHM] (TIMONE), Service de Neurochirurgie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital saint Pierre, GH Sud Réunion, Hôpital de Perpignan, Centre Hospitalier Saint Jean de Perpignan, CHU Limoges, Service de Neurochirurgie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Hospitalier Régional d'Orléans (CHRO), Hôpitaux Civils de Colmar, Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service d'oncologie médicale (CHRU Lille), and Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: surgery, Cancer Research, intracranial, recurrence, Oncology, solitary fibrous tumour, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], hemangiopericytoma, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Background: Intracranial solitary fibrous tumour (iSFT) is an exceptional mesenchymal tumour with high recurrence rates. We aimed to analyse the clinical outcomes of newly diagnosed and recurrent iSFTs.Methods: We carried out a French retrospective multicentre (n = 16) study of histologically proven iSFT cases. Univariate and multivariate Cox models were used to estimate the prognosis value of the age, location, size, WHO grade, and surgical extent on overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS).Results: Eighty-eight patients were included with a median age of 54.5 years. New iSFT cases were treated with gross tumour resection (GTR) (n = 75) or subtotal resection (STR) (n = 9) and postoperative radiotherapy (PORT) (n = 32, 57%). The median follow-up time was 7 years. The median OS, PFS, and LRFS were 13 years, 7 years, and 7 years, respectively. Forty-two patients experienced recurrence. Extracranial metastasis occurred in 16 patients. Median OS and PFS after the first recurrence were 6 years and 15.4 months, respectively. A higher histological grade was a prognosis factor for PFS (p = 0.04) and LRFS (p = 0.03). GTR influenced LRFS (p = 0.03).Conclusion: GTR provided benefits as a first treatment for iSFTs. However, approximately 40% of patients experienced relapse, which remains a challenging state.
Published: 2023
Full Text: View/download PDF

8. Microsurgical DREZotomy for pain related to Pancoast-Tobias syndrome: how I do it?

Author: Arthur Leclerc, Stéphane Derrey, and Evelyne Emery
Subjects: Surgery, Neurology (clinical)
Abstract: Neuralgic pain related to Pancoast-Tobias syndrome can be difficult to treat. An invasive but effective option for management is open cervical DREZotomy.This procedure involves the interruption of the dorsal root entry zone (A delta and C fibers) that sustains the nociceptive pathways. After dura opening, the microsurgical steps are micro incisions of the pia mater under each dorsolateral rootlets and contiguous microcoagulations in the posterolateral sulcus downward to the posterior horn.When properly performed in a well-selected patient, DREZotomy is a safe and effective procedure for treating devastating pain related to Pancoast-Tobias syndrome.
Published: 2022

9. Occipital Nerve Stimulation for Refractory Chronic Cluster Headache: A Cost-Effectiveness Study

Author: Jimmy Voirin, Caroline Roos, Julie Bulsei, Béchir Jarraya, N. Buisset, Jean Régis, Sylvie Raoul, Eric Fontas, Anne Donnet, Aurelie Leplus, Stephan Chabardes, Philippe Rigoard, Stéphane Derrey, Michel Lanteri-Minet, Christian Lucas, Christelle Créac’h, Pierric Giraud, Evelyne Guegan-Massardier, Denys Fontaine, Dominique Valade, François Caire, Sophie Colnat-Coulbois, Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Lille, Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Rouen, Normandie Université (NU), Service de neurochirurgie [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Hôpital Foch [Suresnes], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], CH Colmar, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Neurochirurgie [CHU Limoges], CHU Limoges, Service de Neurochirurgie [CHU Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Medtronic, Centre Hospitalier Universitaire de Nice, Source(s) of financial support: This work has been developed and supported by the Centre Hospitalier Universitaire de Nice through the FHU INOVPAIN consortium (Nice). St Jude Medical‐Abbott and Medtronic have partially supported the study financially but had no role in the study design, data collection, analysis, and reporting., Dr. Fontaine and Dr. Lanteri‐Minet received consultant fees and research grants from Medtronic. Dr. Chabardes and Dr. Derrey have been consultants for Medtronic. Dr. Voirin received consultant fees from Medtronic. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. Dr. Fontaine and Dr. Lanteri‐Minet received consultant fees and research grants from St. Jude‐Abbott. Dr. Chabardes has been a consultant for Boston Scientific. Dr. Raoul is a consultant for Abbott and Boston Scientific. Dr. Voirin and Dr. Fontaine received consultant fees from Boston Scientific. Dr. Lucas has participated on an advisory board with Novartis, Lilly, Amgen, Lundbeck, AbbVie, and TEVA. Dr. Lucas has also served on a speakers' bureau or participated in educational events with Novartis, Teva and Lilly. Dr. Donnet has received consulting fees from Novartis, TEVA, Amgen, and Lilly. Dr. Donnet has also served on a speakers' bureau or participated in educational events with Novartis. These three companies manufacture and commercialize neuromodulation devices that can be used for ONS. Conflict of Interest, Service de Neurochirurgie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), and Service de Neurochirurgie [Poitiers]
Subjects: medicine.medical_specialty, Total cost, Cost effectiveness, Cost-Benefit Analysis, [SDV]Life Sciences [q-bio], Cluster Headache, occipital nerve stimulation, 03 medical and health sciences, Indirect costs, 0302 clinical medicine, medicine, Humans, Peripheral Nerves, Reimbursement, business.industry, Cluster headache, cost-effectiveness analysis, decision-making, General Medicine, Cost-effectiveness analysis, medicine.disease, Anesthesiology and Pain Medicine, Neurology, neuromodulation, Sick leave, Physical therapy, Occipital nerve stimulation, Quality-Adjusted Life Years, Neurology (clinical), business, 030217 neurology & neurosurgery, Chronic cluster headache
Abstract: International audience; Introduction: Occipital nerve stimulation (ONS) is proposed to treat refractory chronic cluster headache (rCCH), but its cost-effectiveness has not been evaluated, limiting its diffusion and reimbursement. Materials and Methods: We performed a before-and-after economic study, from data collected prospectively in a nation-wide registry. We compared the cost-effectiveness of ONS associated with conventional treatment (intervention and postintervention period) to conventional treatment alone (preintervention period) in the same patients. The analysis was conducted on 76 rCCH patients from the French healthcare perspective at three months, then one year by extrapolation. Because of the impact of the disease on patient activity, indirect cost, such as sick leave and disability leave, was assessed second. Results: The average total cost for three months was €7602 higher for the ONS strategy compared to conventional strategy with a gain of 0.07 quality-adjusted life-years (QALY), the incremental cost-effectiveness ratio (ICER) was then €109,676/QALY gained. The average extrapolated total cost for one year was €1344 lower for the ONS strategy (p = 0.5444) with a gain of 0.28 QALY (p < 0.0001), the ICER was then €-4846/QALY gained. The scatter plot of the probabilistic bootstrapping had 80% of the replications in the bottom right-hand quadrant, indicating that the ONS strategy is dominant. The average indirect cost for three months was €377 lower for the ONS strategy (p = 0.1261). Discussion: This ONS cost-effectiveness study highlighted the limitations of a short-time horizon in an economic study that may lead the healthcare authorities to reject an innovative strategy, which is actually cost-effective. One-year extrapolation was the proposed solution to obtain results on which healthcare authorities can base their decisions. Conclusion: Considering the burden of rCCH and the efficacy and safety of ONS, the demonstration that ONS is dominant should help its diffusion, validation, and reimbursement by health authorities in this severely disabled population.
Published: 2021
Full Text: View/download PDF

10. N°197 – Can electrophysiological analysis of subthalamic nucleus oscillations uncover new biomarkers for freezing of gait in Parkinson[StQuote]s disease patients?

Author: Mathieu Yèche, Katia Lehongre, Saoussen Cherif, David Maltête, Stéphane Derrey, Dorian Bannier, Déborah Ziri, Brian Lau, Carine Karachi, and Marie-Laure Welter
Subjects: Neurology, Physiology (medical), Neurology (clinical), Sensory Systems
Published: 2023
Full Text: View/download PDF

11. Intracranial aneurysms in pediatric population: a two-center audit

Author: S. Curey, Camille Di Palma, Alin Borha, T. Metayer, Stéphane Derrey, Evelyne Emery, Elisabeth Garrido, Olivier Langlois, Chrysanthi Papagiannaki, Thomas Gaberel, and Vianney Gilard
Subjects: Adult, Male, Pediatrics, medicine.medical_specialty, Subarachnoid hemorrhage, Adolescent, Population, Audit, Aneurysm, Ruptured, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Aneurysm, Epidemiology, medicine, Humans, cardiovascular diseases, Child, education, Retrospective Studies, education.field_of_study, business.industry, Intracranial Aneurysm, Retrospective cohort study, General Medicine, Subarachnoid Hemorrhage, medicine.disease, Cerebral Angiography, Pediatrics, Perinatology and Child Health, cardiovascular system, Female, Neurology (clinical), Neurosurgery, Presentation (obstetrics), business, 030217 neurology & neurosurgery
Abstract: Intracranial aneurysms (IA) in children are rare, accounting for less than 5% of all IA. Due to their scarcity, the epidemiology is poorly understood and differs from adults in term of clinical presentation, size, location, and origin. Consequently, the treatment strategies are specific and cannot be only based on data from adult series. The aim of our study was to report the characteristics, management, and outcomes of children treated for IA in two university hospitals located in Normandy (France) over the last 17 years and to perform a literature review of this rare pathology.This retrospective study included 18 consecutive children ( 18 years old) admitted with cerebral aneurysm treated in two neurosurgery departments in Normandy, from 2001 to 2018. Computerized tomography and cerebral angiography established the diagnosis. Both endovascular and surgical procedures were discussed in all cases. Data focused on clinical condition at admission, characteristics of the IA, choice of the treatment modalities, and complications. The outcome at follow-up is based on Glasgow outcomes scale (GOS) at 1 year.During the study period, 18 children (mean age: 12.6 years; sex ratio male/female: 2.3) were admitted with 21 IA. Aneurysms had a mean size of 13.6 mm with 4 giant aneurysms and were mostly located in the anterior circulation (16/21). Clinical presentations at onset were sudden symptoms related to a subarachnoid hemorrhage in 13 patients, headaches in 4 patients with giant aneurysm, and asymptomatic in one patient. Among the 13 patients with ruptured IA, 6 presented in poor preoperative condition (Hunt and Hess Grade ≥ 4). Treatment modalities consisted in embolization in 9 patients and surgery in 9 patients including 2 by-pass surgeries in fusiform aneurysms. Complications were similar in the two groups, but two cases of recanalization were observed in the endovascular group. At 1 year of follow-up, 14 children were in good condition (GOS Score 4) and one died. Three children presented associated IA treated by the same technique as initial aneurysm.Pediatric aneurysm is a different pathology compared with adults, occurring more frequently in male population with a higher proportion of giant aneurysms and aneurysms located in the internal carotid bifurcation. The use of endovascular techniques has progressed in the last years, but surgery was proposed for half of our population.
Published: 2021
Full Text: View/download PDF

12. Personality Assessment with Temperament and Character Inventory in Parkinson's Disease

Author: Mathilde Boussac, Christophe Arbus, Olivier Colin, Chloé Laurencin, Alexandre Eusebio, Elodie Hainque, Jean Christophe Corvol, Nathalie Versace, Olivier Rascol, Vanessa Rousseau, Estelle Harroch, Fabienne Ory-Magne, Margherita Fabbri, Caroline Moreau, Anne-Sophie Rolland, Béchir Jarraya, David Maltête, Sophie Drapier, Ana-Raquel Marques, Nicolas Auzou, Thomas Wirth, Mylène Meyer, Bruno Giordana, Mélissa Tir, Tiphaine Rouaud, David Devos, Christine Brefel-Courbon, Pr Luc Defebvre, Dr Nicolas Carriere, Dr Guillaume Grolez, Dr Guillaume Baille, Dr Kreisler, Pr Jean-Pierre Pruvo, Pr Leclerc, Dr Renaud Lopes, Dr Romain Viard, Dr Gregory Kuchcinski, Mr Julien Dumont, Pr Kathy Dujardin, Mme M. Delliaux, Mrs M. Brion, Dr Gustavo Touzet, Pr Nicolas Reyns, Pr Arnaud Delval, Mrs Valerie Santraine, Mrs Marie Pleuvret, Mrs Nolwen Dautrevaux, Mr Victor Laugeais, Thavarak Ouk, Camille Potey, Celine Leclercq, Elise Gers, Jean-Christophe Corvol, null Marie-Vidailhet, Marie-Laure Welter, Lucette Lacomblez, David Grabli, Emmanuel Roze, Yulia Worbe, Cécile Delorme, Hana You, Jonas Ihle, Raquel Guimeraes-Costa, Florence Cormier-Dequaire, Aurélie Méneret, Andréas Hartmann, Louise-Laure Mariani, Stéphane Lehericy, Virginie Czernecki, Fanny Pineau, Frédérique Bozon, Camille Huiban, Eve Benchetrit, Carine Karachi, Soledad Navarro, Philippe Cornu, Arlette Welaratne, Carole Dongmo-Kenfack, Lise Mantisi, Nathalie Jarry, Sophie Aix, Carine Lefort, Dr Tiphaine Rouaud, Pr Philippe Damier, Pr Pascal Derkinderen, Dr Anne-Gaelle Corbille, Dr Elisabeth Calvier-Auffray, Mrs Laetitia Rocher, Mrs Anne-Laure Deruet, Dr Raoul Sylvie, Dr Roualdes Vincent, Mrs Le Dily Séverine, Dr Ana Marques, Dr Berangere Debilly, Pr Franck Durif, Dr Philippe Derost, Dr Charlotte Beal, Carine Chassain, Laure Delaby, Tiphaine Vidal, Pr Jean Jacques Lemaire, Isabelle Rieu, Elodie Durand, Pr Alexandre Eusebio, Pr Jean-Philippe Azulay, Dr Tatiana Witjas, Dr Frédérique Fluchère, Dr Stephan Grimaldi, Pr Nadine Girard, Marie Delfini, Dr Romain Carron, Pr Jean Regis, Dr Giorgio Spatola, Camille Magnaudet, Dr Ansquer Solène, Dr Benatru Isabelle, Dr Colin Olivier, Pr Houeto Jl, Pr Guillevin Remy, Mrs Fradet Anne, Mrs Anziza Manssouri, Mrs Blondeau Sophie, Dr Richard Philippe, Dr Cam Philippe, Dr Page Philippe, Pr Bataille Benoit, Mrs Rabois Emilie, Mrs Guillemain Annie, Dr Drapier Sophie, Dr Frédérique Leh, Dr Alexandre Bonnet, Pr Marc Vérin, Dr Jean-Christophe Ferré, Mr Jean François Houvenaghel, Pr Claire Haegelen, Mrs Francoise Kestens, Mrs Solenn Ory, Pr Pierre Burbaud, Dr Nathalie Damon-Perriere, Pr Wassilios Meissner, Pr Francois Tison, Dr Stéphanie Bannier, Dr Elsa Krim, Pr Dominique Guehl, Sandrine Molinier-Blossier, Morgan Ollivier, Marion Lacoste, Marie Bonnet, Pr Emmanuel Cuny, Dr Julien Engelhardt, Olivier Branchard, Clotilde Huet, Julie Blanchard, Pr Rascol Olivier, Dr Christine Brefel Courbon, Dr Fabienne Ory Magne, Dr Marion Simonetta Moreau, Pr Christophe Arbus, Pr Fabrice Bonneville, Dr Jean Albert Lotterie, Marion Sarrail, Charlotte Scotto d’Apollonia, Pr Patrick Chaynes, Pr François Caire, Pr David Maltete, Dr Romain Lefaucheur, Dr Damien Fetter, Dr Nicolas Magne, Mrs Sandrine Bioux, Mrs Maud Loubeyre, Mrs Evangéline Bliaux, Mrs Dorothée Pouliquen, Pr Stéphane Derrey, Mrs Linda Vernon, Dr Frédéric Ziegler, Mathieu Anheim, Ouhaid Lagha-Boukbiza, Christine Tranchant, Odile Gebus, Solveig Montaut, S. Kremer, Nadine Longato, Clélie Phillips, Jimmy Voirin, Marie des Neiges Santin, Dominique Chaussemy, Dr Amaury Mengin, Dr Caroline Giordana, Dr Claire Marsé, Lydiane Mondot, Robin Kardous, Bernadette Bailet, Héloise Joly, Denys Fontaine, Dr Aurélie Leplus, Amélie Faustini, Vanessa Ferrier, Pr Pierre Krystkowiak, Dr Mélissa Tir, Pr Jean-Marc Constans, Sandrine Wannepain, Audrey Seling, Dr Michel Lefranc, Stéphanie Blin, Béatrice Schuler, Pr Stephane Thobois, Dr Teodor Danaila, Dr Chloe Laurencin, Pr Yves Berthezene, Dr Roxana Ameli, Helene Klinger, Dr Gustavo Polo, Patrick Mertens, A. Nunes, Elise Metereau, Dr Lucie Hopes, Dr Solène Frismand, Dr Emmanuelle Schmitt, Mrs Mylène Meyer, Mrs Céline Dillier, Pr Sophie Colnat, Mrs Anne Chatelain, Dr Jean- Philippe Brandel, Dr Cécile Hubsch, Dr Patte Karsenti, Dr Marie Lebouteux, Dr Marc Ziegler, Dr Christine Delmaire, Dr Julien Savatowky, Mrs Juliette Vrillac, Mrs Claire Nakache, Dr Vincent D'Hardemare, Mr Lhaouas Belamri, Dr Valérie Mesnage, Dr Cécilia Bonnet, Dr Jarbas Correa Lino, Dr Camille Decrocq, Dr Anne Boulin, Mrs Inès Barre, Mrs Jordane Manouvrier, Dr Bérénice Gardel, Pr Béchir Jarraya, Mrs Catherine Ziz, Mrs Lydie Prette, Mr Hassen Douzane, David Gay, Robin Bonicel, Fouzia El Mountassir, Clara Fischer, Jean-François Mangin, Marie Chupin, Yann Cointepas, Bertrand Accart, Patrick Gelé, Florine Fievet, Matthieu Chabel, Virginie Derenaucourt, Loïc Facon, Yanick Tchantchou Njosse, Dominique Deplanque, Alain Duhamel, Lynda Djemmane, Florence Duflot, Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier de Brive-la-Gaillarde (CH Brive), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon, Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Marseille, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d’Excellence en Maladies Neurodégénératives (NeuroToul), CIC - Biotherapie - Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Lille, Service NEUROSPIN (NEUROSPIN), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Hôpital Foch [Suresnes], Neuroimagerie cognitive - Psychologie cognitive expérimentale (UNICOG-U992), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), CHU Bordeaux [Bordeaux], Les Hôpitaux Universitaires de Strasbourg (HUS), Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Amiens-Picardie, Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), Centre hospitalier universitaire de Nantes (CHU Nantes), This work was supported by the France Parkinson charity and French Ministry of Health (PHRC national 2012). This is an ancillary study to Protocol ID: 2013-A00193-42, ClinicalTrials.gov: NCT02360683., Centre Hospitalier Brive-la-Gaillarde, and Hôpital P.P.-Riquet
Subjects: Personality Inventory, Temperament and character inventory, Parkinson's disease, Parkinson Disease, Personality Assessment, Antidepressive Agents, Neurology, Anti-Anxiety Agents, Fluctuating PD patients, Quality of Life, Humans, Neurology (clinical), Geriatrics and Gerontology, Temperament, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Personality
Abstract: International audience; INTRODUCTION: There is a growing interest in personality evaluation in Parkinson's disease (PD), following observations of specific temperaments in PD patients. Therefore, our objective was to evaluate personality dimensions from the Temperament and Character Inventory (TCI) in a cohort of fluctuating PD patients considered for deep brain stimulation. METHODS: Fluctuating PD patients from the PREDISTIM cohort were included. Description of TCI dimensions and comparison with a French normative cohort were performed. Pearson correlations between TCI dimensions and motor, behavioral and cognitive variables were investigated. Structural and internal consistency analysis of the TCI were further assessed. RESULTS: The 570 PD patients presented significant higher scores in Harm Avoidance, Reward Dependence, Persistence, Self-Directedness and Cooperativeness and significant lower scores in Self-Transcendence compared to the French normative cohort; only Novelty Seeking scores were not different. Harm Avoidance and Self-directedness scores were correlated with PDQ-39 total, HAMD, HAMA scores, and anxiolytic/antidepressant treatment. Novelty Seeking scores were correlated with impulsivity. Pearson correlations between TCI dimensions, principal component analysis of TCI sub-dimensions and Cronbach's alpha coefficients showed adequate psychometric proprieties. CONCLUSION: The TCI seems to be an adequate tool to evaluate personality dimensions in PD with good structural and internal consistencies. These fluctuating PD patients also have specific personality dimensions compared to normative French population. Moreover, Harm Avoidance and Self-Directedness scores are associated with anxio-depressive state or quality of life and, and Novelty Seeking scores with impulsivity.
Published: 2022
Full Text: View/download PDF

13. Practice of stereoelectroencephalography (sEEG) in drug-resistant epilepsy: Retrospective series with surgery and thermocoagulation outcomes

Author: Nathalie Chastan, Stéphane Derrey, F. Le Goff, J.-L. Méreaux, A. Lebas, V. Gilard, Nicolas Magne, Emmanuel Gerardin, David Maltête, Service de neurochirurgie [CHU Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de neurophysiologie [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), and Service de Radiologie [CHU Rouen]
Subjects: Male, Drug Resistant Epilepsy, medicine.medical_specialty, Adolescent, Vagus Nerve Stimulation, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Electroencephalography, Neurosurgical Procedures, Stereoelectroencephalography, Stereotaxic Techniques, Young Adult, 03 medical and health sciences, Epilepsy, 0302 clinical medicine, Hematoma, Seizures, Electrocoagulation, medicine, Humans, Epilepsy surgery, Age of Onset, Child, Retrospective Studies, Cerebral Cortex, medicine.diagnostic_test, business.industry, Palliative Care, medicine.disease, Epileptogenic zone, Electrodes, Implanted, Surgery, Treatment Outcome, Child, Preschool, 030220 oncology & carcinogenesis, Female, Neurology (clinical), Nervous System Diseases, business, 030217 neurology & neurosurgery, Vagus nerve stimulation
Abstract: Objective The aim of this study was to determine the success rate of sEEG in locating the epileptogenic zone (EZ) in patients with pharmaco-resistant epilepsy. Secondary objectives were to analyze sEEG-related morbidity and outcomes for post-sEEG thermocoagulation and cortical resection. Methods Data were collected on 49 sEEGs from 46 consecutive patients between 2010 and 2018. Following sEEG, either resective or palliative surgery with vagus nerve stimulation was performed. In 8 patients, EZ thermocoagulation was performed before EEG leads were withdrawn. Outcomes were collected based on the Engel and ILAE outcome scales. Results sEEG was contributive in 45 of 49 recordings, with a success rate of 92% in locating the EZ. Minor complications, such as transient neurologic deficit and electrode implantation failures, occurred in 6%. One major complication occurred, with death due to atypical late hematoma. Thermocoagulation was performed in 8 patients and stopped or significantly reduced seizure frequency in 7 (88%). Outcome of surgical resection (n = 33) was good, with 20 (61%) seizure-free patients and 32 (97%) with definite improvement. Conclusions Our findings suggest that sEEG is an effective technique for EZ location in patients with drug-resistant epilepsy. sEEG was contributive in up to 92% of patients, allowing thermocoagulation and/or surgical resection that resulted in seizure-freedom in two-thirds and seizure-reduction in one-third of cases. This study highlights the need for strict selection of implantation candidates, with strong initial hypothesis as to EZ location.
Published: 2020
Full Text: View/download PDF

14. Tumor-to-tumor metastases: Latent renal cell carcinoma discovered after elective surgical resection of a convexity meningioma

Author: Annie Laquerrière, Florent Marguet, Radu Pirlog, Octavian Mihai Sirbu, Mathieu Lozouet, Elsa Billaud-Porte, S. Curey, and Stéphane Derrey
Subjects: medicine.medical_specialty, business.industry, Brain Neoplasms, Brain tumor, Meningothelial Meningioma, medicine.disease, Magnetic Resonance Imaging, Metastasis, Meningioma, Lesion, Clear cell renal cell carcinoma, Renal cell carcinoma, medicine, Meningeal Neoplasms, Humans, Surgery, Neurology (clinical), Radiology, Differential diagnosis, medicine.symptom, business, Carcinoma, Renal Cell, Aged
Abstract: Background: Tumor-to-tumor metastases are extremely rarely reported lesions which usually involve an indolent lesion hosting a more aggressive neoplasm. We present an unusual initial manifestation of a previously unknown clear cell renal cell carcinoma as a tumor-to-tumor metastasis in a typical meningothelial meningioma. Case report: A 73-year old patient with transient left slight monoparesis was addressed to our Neurosurgical Department after being evaluated by his general practitioner and passing a cerebral MRI which revealed a right frontotemporal mass attached to the meninge. At presentation, no deficits were identified; therefore an elective surgery was proposed. Histological analysis revealed a typical meningothelial meningioma containing a metastatic clear cell renal cell carcinoma. Additional thoraco-abdominal computer tomography identified a 6 cm diameter lesion within the right kidney with radiological features highly suggestive of a primary clear cell renal cell carcinoma. Conclusion: Our case highlights the need for a specialized neuropathological approach to clinical and imagistic indolent meningiomas, as they may require important differential diagnosis that can highly impact the treatment and follow-up of brain tumor patients.
Published: 2021

15. Diagnosis and Management of Glioblastoma: A Comprehensive Perspective

Author: Annie Laquerrière, Abdellah Tebani, Vianney Gilard, Maxime Fontanilles, Stéphane Marret, Ivana Dabaj, Stéphane Derrey, and Soumeya Bekri
Subjects: Oncology, medicine.medical_specialty, medicine.medical_treatment, lcsh:Medicine, Medicine (miscellaneous), personalized therapies, Review, 03 medical and health sciences, 0302 clinical medicine, Quality of life, molecular pathology, Internal medicine, medicine, In patient, Chemotherapy, Molecular pathology, business.industry, Incidence (epidemiology), pathogenesis, lcsh:R, glioblastoma, Cancer, medicine.disease, Omics, omics, 030220 oncology & carcinogenesis, business, 030217 neurology & neurosurgery, Glioblastoma
Abstract: Glioblastoma is the most common malignant brain tumor in adults. The current management relies on surgical resection and adjuvant radiotherapy and chemotherapy. Despite advances in our understanding of glioblastoma onset, we are still faced with an increased incidence, an altered quality of life and a poor prognosis, its relapse and a median overall survival of 15 months. For the past few years, the understanding of glioblastoma physiopathology has experienced an exponential acceleration and yielded significant insights and new treatments perspectives. In this review, through an original R-based literature analysis, we summarize the clinical presentation, current standards of care and outcomes in patients diagnosed with glioblastoma. We also present the recent advances and perspectives regarding pathophysiological bases as well as new therapeutic approaches such as cancer vaccination and personalized treatments.
Published: 2021

16. Nucleus Basalis of Meynert Stimulation for Lewy Body Dementia: A Phase I Randomized Clinical Trial

Author: Julie Bourilhon, Olivier Godefroy, Luc Defebvre, Didier Hannequin, Romain Lefaucheur, Stéphane Derrey, Stéphane Thobois, Pierre Vera, Jean-Luc Houeto, Kathy Dujardin, André Gillibert, David Wallon, Teodor Danaila, Olivier Martinaud, Pierre Krystkowiak, Marie-Laure Welter, Mathieu Chastan, David Maltête, Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), and Normandie Université (NU)
Subjects: Male, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Deep Brain Stimulation, MESH: Mental Recall, Stimulation, Neuropsychological Tests, Nucleus basalis, law.invention, Lingual gyrus, 0302 clinical medicine, Postoperative Complications, Randomized controlled trial, MESH: Fluorodeoxyglucose F18, law, MESH: Postoperative Complications, MESH: Double-Blind Method, 030212 general & internal medicine, MESH: Treatment Outcome, MESH: Aged, MESH: Middle Aged, Cross-Over Studies, Brain, MESH: Neuropsychological Tests, Middle Aged, MESH: Positron-Emission Tomography, surgical procedures, operative, Implantable Neurostimulators, Treatment Outcome, Anesthesia, Basal Nucleus of Meynert, MESH: Basal Nucleus of Meynert, therapeutics, MESH: Radiopharmaceuticals, Lewy Body Disease, Deep brain stimulation, MESH: Sleep, MESH: Prosthesis Implantation, behavioral disciplines and activities, MESH: Cross-Over Studies, Article, Prosthesis Implantation, MESH: Brain, 03 medical and health sciences, Double-Blind Method, Fluorodeoxyglucose F18, medicine, Dementia, Humans, MESH: Lewy Body Disease, Aged, MESH: Humans, Lewy body, business.industry, medicine.disease, MESH: Male, MESH: Implantable Neurostimulators, nervous system diseases, nervous system, Positron-Emission Tomography, Mental Recall, Neurology (clinical), MESH: Deep Brain Stimulation, Radiopharmaceuticals, business, Sleep, 030217 neurology & neurosurgery, Stroop effect
Abstract: ObjectivesNucleus basalis of Meynert deep brain stimulation (NBM-DBS) has been proposed for patients with dementia. Here, we aim to assess the safety and effects of NBM-DBS in patients with Lewy body dementia (LBD), in a randomized, double-blind, crossover clinical trial.MethodsSix patients with mild to moderate LBD (mean [SD] age, 62.2 [7.8] years) were included, operated on for bilateral NBM-DBS, and assigned to receive either active or sham NBM-DBS followed by the opposite condition for 3 months. The primary outcome was the difference in the total free recalls of the Free and Cued Selective Reminding Test (FCSRT) between active and sham NBM-DBS. Secondary outcomes were assessments of the safety and effects of NBM-DBS on cognition, motor disability, sleep, and PET imaging.ResultsThere was no significant difference in the FCSRT score with active vs sham NBM-DBS. The surgical procedures were well tolerated in all patients, but we observed significant decreases in Stroop and Benton scores after electrode implantation. We observed no significant difference in other scales between active and sham NBM-DBS. With active NBM-DBS relative to baseline, phonemic fluency and motor disability significantly decreased. Lastly, the superior lingual gyrus metabolic activity significantly increased with active NBM-DBS.ConclusionsNBM-DBS does not appear to be totally safe for patients with LBD with no evidence of cognitive benefit.ClinicalTrials.gov IdentifierNCT01340001.Classification of EvidenceThis study provides Class II evidence that, for patients with LBD operated on for bilateral NBM-DBS, active NBM-DBS stimulation compared to sham stimulation did not significantly change selective recall scores.
Published: 2021
Full Text: View/download PDF

17. Long-Term Efficacy of Occipital Nerve Stimulation for Medically Intractable Cluster Headache

Author: Christian Lucas, Christelle Créac’h, Béchir Jarraya, N. Buisset, Dominique Valade, François Caire, Pierric Giraud, Laurie Tran, Stephan Chabardes, Jean Régis, Stéphane Derrey, Aurelie Leplus, Frederic Bourdain, Anne Donnet, Sylvie Raoul, Jimmy Voirin, Caroline Roos, Jocelyne Bloch, Michel Lanteri-Minet, Philippe Rigoard, Evelyne Guegan-Massardier, Denys Fontaine, Bich Dang-Vu, Sophie Colnat-Coulbois, Coralie Cruzel, Serge Blond, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
Subjects: Adult, Quality of life, medicine.medical_specialty, Cluster headache, Visual analogue scale, Electric Stimulation Therapy, 03 medical and health sciences, 0302 clinical medicine, Occipital nerve stimulation, Refractory, 030202 anesthesiology, Internal medicine, Humans, Medicine, Peripheral Nerves, Aged, Intractable, business.industry, Neuromodulation, Middle Aged, medicine.disease, 3. Good health, Treatment Outcome, Migraine, Anxiety, Female, Surgery, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Neurology (clinical), medicine.symptom, business, Complication, 030217 neurology & neurosurgery
Abstract: International audience; BACKGROUND: Occipital nerve stimulation (ONS) has been proposed to treat refractory chronic cluster headache (rCCH) but its efficacy has only been showed in small short-term series. OBJECTIVE: To evaluate ONS long-term efficacy in rCCH. METHODS: We studied 105 patients with rCCH, treated by ONS within a multicenter ONS prospective registry. Efficacy was evaluated by frequency, intensity of pain attacks, quality of life (QoL) EuroQol 5 dimensions (EQ5D), functional (Headache Impact Test-6, Migraine Disability Assessment) and emotional (Hospital Anxiety Depression Scale [HAD]) impacts, and medication consumption. RESULTS: At last follow-up (mean 43.8 mo), attack frequency was reduced >50% in 69% of the patients. Mean weekly attack frequency decreased from 22.5 at baseline to 9.9 (P
Published: 2021
Full Text: View/download PDF

18. French guidelines on stereoelectroencephalography (SEEG)

Author: Agnès Trébuchon, Vincent Navarro, Hélène Catenoix, Fabrice Bartolomei, Louis Maillard, Aileen McGonigal, Axel Lebas, Francine Chassoux, Delphine Taussig, William Szurhaj, Anne-Sophie Job-Chapron, Maria Paola Valenti-Hirsch, Lorella Minotti, Anca Nica, Mathilde Chipaux, Luc Valton, Vianney Gilard, Stéphane Derrey, Marc Guénot, Jean-Christophe Sol, Julia Scholly, Georg Dorfmüller, Pierre Bourdillon, Marie Denuelle, Stéphane Clemenceau, Jean-Pierre Vignal, Nicolas Reyns, Louise Tyvaert, Bertrand Devaux, Alexandra Montavont, Sophie Colnat-Coulbois, Paul Sauleau, Elisabeth Landré, Jean Isnard, CHU Lille, CNRS, Inserm, Université de Lille, Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189, Troubles cognitifs dégénératifs et vasculaires - U1171, Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI], Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV], Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physiologie-Explorations Fonctionnelles, Université de Rennes (UR), Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de neuro-chirurgie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre Hospitalier Saint-Anne (GHU Paris), Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Service de neurochirurgie pédiatrique [Fondation Rothschild, Paris], Fondation Ophtalmologique Adolphe de Rothschild [Paris], Endothélium microcirculatoire cérébral et lésions du système nerveux central au cours du développement (Néovasc), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie [Lyon], CHU Lyon, Université de Lyon, [GIN] Grenoble Institut des Neurosciences (GIN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), Centre de Recherche en Automatique de Nancy (CRAN), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Strasbourg, Troubles cognitifs dégénératifs et vasculaires - U 1171 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de recherche cerveau et cognition (CERCO), Institut des sciences du cerveau de Toulouse. (ISCT), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Comportement et noyaux gris centraux = Behavior and Basal Ganglia [Rennes], Université de Rennes (UR)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes = Institute of Clinical Neurosciences of Rennes (INCR), The authors would like to thank the Société de Neurophysiologie Clinique de Langue Française (SNCLF) and the Ligue Française Contre l’Épilepsie (LFCE) for their logistic and financial support for this work., Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre Hospitalier Saint-Anne, Service de Neurochirurgie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Toulouse [Toulouse], Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation Rothschild, Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes (INCR), Centre de recherche en neurosciences de Lyon ( CRNL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] ( UJM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de Neurosciences des Systèmes ( INS ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau ( ADEN ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Endothélium microcirculatoire cérébral et lésions du système nerveux central au cours du développement ( Néovasc ), Institute for Research and Innovation in Biomedicine ( IRIB ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Grenoble Institut des Neurosciences ( GIN ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Centre Hospitalier Universitaire [Grenoble] ( CHU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Recherche en Automatique de Nancy ( CRAN ), Université de Lorraine ( UL ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Traitement du Signal et de l'Image ( LTSI ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Troubles cognitifs dégénératifs et vasculaires ( DN2M ), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ) -INSERM, Centre de recherche cerveau et cognition ( CERCO ), Université Paul Sabatier - Toulouse 3 ( UPS ) -Centre National de la Recherche Scientifique ( CNRS ), Comportement et noyaux gris centraux [Rennes], Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Université européenne de Bretagne ( UEB ) -CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes (INCR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Centre Hospitalier Saint-Anne, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Cortex et Epilepsie [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU), Service de neurochirurgie [Rouen], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Hôpital Sainte-Anne, Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Troubles cognitifs dégénératifs et vasculaires (U1171), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-INSERM, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut des sciences du cerveau de Toulouse. (ISCT), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J)-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Institut des Neurosciences Cliniques de Rennes (INCR)-CHU Pontchaillou [Rennes]-Université européenne de Bretagne - European University of Brittany (UEB)-Université de Rennes 1 (UR1)
Subjects: Drug Resistant Epilepsy, medicine.medical_specialty, Drug-resistant epilepsy, Adults, Thermocoagulations, Stereo-electroencephalogram, Invasive exploration, Guidelines, Focal epilepsy, Epilepsy surgery, Children, Guidelines as Topic, Stereoelectroencephalography, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Epileptic discharge, 0302 clinical medicine, Physiology (medical), Electrocoagulation, medicine, Humans, Medical physics, [ SDV.IB ] Life Sciences [q-bio]/Bioengineering, Focal Epilepsies, Electroencephalography, General Medicine, Electrodes, Implanted, 3. Good health, Clinical Practice, Neurology, Current practice, [SDV.IB]Life Sciences [q-bio]/Bioengineering, France, Neurology (clinical), Psychology, International league against epilepsy, 030217 neurology & neurosurgery
Abstract: International audience; Stereoelectroencephalography (SEEG) was designed and developed in the 1960s in France by J. Talairach and J. Bancaud. It is an invasive method of exploration for drug-resistant focal epilepsies, offering the advantage of a tridimensional and temporally precise study of the epileptic discharge. It allows anatomo-electrical correlations and tailored surgeries. Whereas this method has been used for decades by experts in a limited number of European centers, the last ten years have seen increasing worldwide spread of its use. Moreover in current practice, SEEG is not only a diagnostic tool but also offers a therapeutic option, i.e., thermocoagulation. In order to propose formal guidelines for best clinical practice in SEEG, a working party was formed, composed of experts from every French centre with a large SEEG experience (those performing more than 10 SEEG per year over at least a 5 year period). This group formulated recommendations, which were graded by all participants according to established methodology. The first part of this article summarizes these within the following topics: indications and limits of SEEG; planning and management of SEEG; surgical technique; electrophysiological technical procedures; interpretation of SEEG recordings; and SEEG-guided radio frequency thermocoagulation. In the second part, those different aspects are discussed in more detail by subgroups of experts, based on existing literature and their own experience. The aim of this work is to present a consensual French approach to SEEG, which could be used as a basic document for centers using this method, particularly those who are beginning SEEG practice. These guidelines are supported by the French Clinical Neurophysiology Society and the French chapter of the International League Against Epilepsy.
Published: 2018
Full Text: View/download PDF

19. Precision Neurosurgery: A Path Forward

Author: Abdellah Tebani, Stéphane Marret, Vianney Gilard, Stéphane Derrey, and Soumeya Bekri
Subjects: medicine.medical_specialty, Engineering, business.industry, precision medicine, Big data, medical imaging, Medicine (miscellaneous), Review, personalized medicine, Precision medicine, omics, SAFER, Health care, medicine, Medicine, Profiling (information science), Engineering ethics, neurosurgery, Convergence (relationship), Neurosurgery, Personalized medicine, business, neuro-oncology
Abstract: Since the inception of their profession, neurosurgeons have defined themselves as physicians with a surgical practice. Throughout time, neurosurgery has always taken advantage of technological advances to provide better and safer care for patients. In the ongoing precision medicine surge that drives patient-centric healthcare, neurosurgery strives to effectively embrace the era of data-driven medicine. Neuro-oncology best illustrates this convergence between surgery and precision medicine with the advent of molecular profiling, imaging and data analytics. This convenient convergence paves the way for new preventive, diagnostic, prognostic and targeted therapeutic perspectives. The prominent advances in healthcare and big data forcefully challenge the medical community to deeply rethink current and future medical practice. This work provides a historical perspective on neurosurgery. It also discusses the impact of the conceptual shift of precision medicine on neurosurgery through the lens of neuro-oncology.
Published: 2021
Full Text: View/download PDF

20. P13.10 Chemoattraction of glioma cells in a local hydrogel trap and immune control associated with improved survival and cognitive functions in a mouse model of glioblastoma resection

Author: Laurence Desrues, Kleouforo Paul Dembele, Martine Dubois, Hélène Castel, F Ferracci, E Laillet De Montulle, Alexandre Mutel, Olivier Langlois, Stéphane Derrey, Pierrick Gandolfo, O Chever, and Fabrice Morin
Subjects: Cancer Research, business.industry, Improved survival, Immune control, medicine.disease, Resection, Trap (computing), Oncology, Glioma, medicine, Cancer research, Neurology (clinical), business, Glioblastoma
Abstract: BACKGROUND Glioblastoma (GB) is the most aggressive brain primary tumor. The prognosis remains poor mainly due to the invasiveness of glioma cells, radio and/or chemoresistance and GB-induced immunosuppressive environment. Here, we propose to use a local delivery system based on a biocompatible hydrogel containing the chemopeptide urotensin II (hUII) or a biased synthetic analog DAB8-hUII, to “trap” GB cells, and/or to control immune cells expressing its G protein-coupled receptor UT, leading to tumor regression and neurological benefit, in a mouse model of GB resection. MATERIAL AND METHODS In vitro, invasion towards UII/analog across different hydrogels or glue of human or murine GB-GFP cell lines was evaluated in Boyden chamber and cloning ring assays. In vivo GB cells were intrastriatally xenografted, then resected while hydrogel- or glue-containing UII/analog was injected in the cavity resection. Behavioral tests, brain immunohistochemical analyses and mouse survival were then investigated. RESULTS In vitro, invasive capacity of human U87 and 42MG or murine GL261 and CT2A GB cells was stimulated by UII loaded into hydrogel-based hyaluronic acid supplemented with collagen or other chemicals, PNIPAAm-PEG, or thrombin-fibrin glue. In vivo, injection of UII- or DAB8-hUII-loaded glue into the cavity resection of GL261 and CT2A GB in C57BL/6 mice significantly improved survival compared with tumor and resected experimental conditions. Neurological status was also tested before and after GB resection. We found that GL261 and CT2A cell-bearing mice expressed altered spontaneous activity, emotion and cognitive functions. Intracavity injection of the glue improved resignation and anxiety and increased motor activity and cognition with a best cognitive recovery with hUII and DAB-8-hUII-loaded glue groups. Ex vivo brain analyses revealed high expression of UT and UII in some GB GFP-positive cells and macrophages within GB core and at the interface with the normal brain, GB cells expressing UT migrating along tortuous podocalyxin+ vascular components. In brains bearing hydrogel/hUII glue, vascularization appears modified and GFAP+ astrocytes and F4/80+ macrophages were highly recruited in the border of the cavity, compared with the other conditions. CONCLUSION A local glue containing UII may trap GB cells and remodel the tumor microenvironment responsible for survival and cognitive improvements, providing new option in the therapeutic arsenal of GB.
Published: 2021
Full Text: View/download PDF

21. Management and outcome of cerebral venous thrombosis after head trauma: A case series

Author: S. Curey, A. Triquenot, V. Gilard, Ozlem Ozkul-Wermester, Romain Lefaucheur, Lou Grangeon, Emmanuel Gerardin, Stéphane Derrey, David Maltête, Nicolas Magne, Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de neurochirurgie [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service d'imagerie médicale [CHU Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen]-CHU Rouen, Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), and UNIROUEN - UFR Santé (UNIROUEN UFR Santé)
Subjects: Adult, Male, medicine.medical_specialty, Traumatic Hemorrhage, Head trauma, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], medicine, Craniocerebral Trauma, Humans, Thrombolytic Therapy, ComputingMilieux_MISCELLANEOUS, Sinus (anatomy), business.industry, Head injury, Anticoagulants, medicine.disease, 3. Good health, Surgery, Venous thrombosis, Skull, Treatment Outcome, medicine.anatomical_structure, Neurology, 030220 oncology & carcinogenesis, Radiological weapon, Disease Progression, Neurology (clinical), Intracranial Thrombosis, Complication, business, 030217 neurology & neurosurgery
Abstract: Cerebral venous thrombosis (CVT) is an underdiagnosed complication of head trauma. To date, initiation of anticoagulation is still a matter of debate because of the risk of worsening traumatic hemorrhage. This report describes a case series of five patients admitted for head injury complicated by CVT. The main associated radiological signs were skull fractures crossing the venous sinus and adjacent traumatic hematoma. In four patients, anticoagulation was introduced within 48-72h of CVT diagnosis, with no subsequent hemorrhagic complications. The present report and data from the literature raise the question of systematic additional venoscans when confronted by associated radiological features of post-traumatic CVT. The safety of anticoagulation in selected patients is also discussed.
Published: 2017
Full Text: View/download PDF

22. Cover Image

Author: Guillaume Costentin, Stéphane Derrey, Emmanuel Gérardin, Yohann Cruypeninck, Thibaut Pressat‐Laffouilhere, Youssef Anouar, David Wallon, Floriane Le Goff, Marie‐Laure Welter, and David Maltête
Subjects: Neurology, Radiological and Ultrasound Technology, Radiology, Nuclear Medicine and imaging, Neurology (clinical), Anatomy, Cover Image
Abstract: [Image: see text] COVER ILLUSTRATION 3D reconstruction and axial slices of one subject's brain in MNI 152 space. Tracts involved in verbal fluency which are disrupted along the trajectories of electrodes implanted for subthalamic deep brain stimulation in Parkinson's disease are represented. Blue on 3D reconstruction : Superior Longitudinal Tract, orange : Inferior Longitudinal Tract, green : Arcuate Fasciculus, light blue on axial slice : Anterior Thalamic Radiation and violet : Fronto‐striatal Tract.
Published: 2019
Full Text: View/download PDF

23. White matter tracts lesions and decline of verbal fluency after deep brain stimulation in Parkinson's disease

Author: David Wallon, Floriane Le Goff, Youssef Anouar, Stéphane Derrey, Guillaume Costentin, Yohann Cruypeninck, Marie-Laure Welter, David Maltête, Emmanuel Gerardin, Thibaut Pressat-Laffouilhere, Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de neurochirurgie [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Service d'imagerie médicale [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Unité de biostatistiques [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Différenciation et communication neuronale et neuroendocrine (DC2N), and Service de neurophysiologie [Rouen]
Subjects: Adult, Male, Parkinson's disease, Deep brain stimulation, medicine.medical_treatment, Deep Brain Stimulation, Neuroimaging, 050105 experimental psychology, Lesion, White matter, 03 medical and health sciences, 0302 clinical medicine, Subthalamic Nucleus, Neural Pathways, medicine, Verbal fluency test, Humans, 0501 psychology and cognitive sciences, Radiology, Nuclear Medicine and imaging, Cognitive Dysfunction, Inferior longitudinal fasciculus, Research Articles, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, Radiological and Ultrasound Technology, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, 05 social sciences, Superior longitudinal fasciculus, Parkinson Disease, Anatomy, Middle Aged, medicine.disease, Magnetic Resonance Imaging, White Matter, Electrodes, Implanted, Subthalamic nucleus, medicine.anatomical_structure, Neurology, nervous system, Neurology (clinical), medicine.symptom, business, 030217 neurology & neurosurgery
Abstract: Decline of verbal fluency (VF) performance is one of the most systematically reported neuropsychological adverse effects after subthalamic nucleus deep brain stimulation (STN-DBS). It has been suggested that this worsening of VF may be related to a microlesion due to the electrode trajectories. We describe the disruption of surrounding white matter tracts following electrode implantation in Parkinson's disease (PD) patients with STN-DBS and assess whether damage of fiber pathways is associated with VF impairment after surgery. We retrospectively analyzed 48 PD patients undergoing bilateral STN DBS. The lesion mask along the electrode trajectory transformed into the MNI 152 coordinate system, was compared with white matter tract atlas in Tractotron software, which provides a probability and proportion of fibers disconnection. Combining tract- and atlas-based analysis reveals that the trajectory of the electrodes intersected successively with the frontal aslant tract, anterior segment of arcuate tract, the long segment of arcuate tract, the inferior longitudinal fasciculus, the superior longitudinal fasciculus, the anterior thalamic radiation, and the fronto striatal tract. We found no association between the proportion fiber disconnection and the severity of VF impairment 6 months after surgery. Our findings demonstrated that microstructural injury associated with electrode trajectories involved white matter bundles implicated in VF networks.
Published: 2019
Full Text: View/download PDF

24. [Low-grade dural extranodal marginal zone lymphoma]

Author: Florent, Marguet, Maxime, Fontanilles, Elodie, Bohers, Stéphane, Derrey, Olivier, Langlois, Liana, Veresezan, Stéphane, Leprêtre, Jean-Christophe, Sabourin, Fabrice, Jardin, and Annie, Laquerrière
Subjects: Adult, Diagnosis, Differential, Male, Biomarkers, Tumor, Humans, Female, Lymphoma, B-Cell, Marginal Zone, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Aged
Abstract: Primary low-grade dural marginal zone lymphoma is an indolent low grade lymphoma occurring especially among middle-aged immunocompetent women, and is not associated to an infectious process, contrary to gastric or intestinal marginal zone lymphomas. Dural location is rare since only 105 cases have been reported so far. We report herein on two additional cases, a 72-year-old woman and a 36-year-old man whose lymphoma was revealed by partial seizures and headaches. Morphological analysis of surgical specimens displayed a tumoral proliferation made of small lymphocytes arranged in sheets or in nodules with CD20, CD79a and BCL2-immunopositivity, but CD5 and CD10 negativity. Molecular analysis using a panel of 34 genes involved in lymphomagenesis disclosed a deletion of SOCS1 and TNFAIP3 genes, implicated in the JAK/STAT and NFκB pathways respectively in the first patient that could explain unfavourable prognosis despite complementary radiotherapy. No anomaly was identified in the second patient who is alive with no recurrence or progression seven years after the diagnosis. Currently, there are no standardized treatment schedules, but the vast majority of patients are treated by surgery, then radiotherapy followed by adjuvant chemotherapy using methotrexate alone or in combination with rituximab. Literature review indicates that five-year survival has been estimated at 96.7%, suggesting a better prognosis compared to other locations.
Published: 2019

25. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease

Author: Stéphane Thobois, Marie Vidailhet, Stéphane Derrey, Andrea Kistner, Philippe Damier, Daniel Weiss, W.M. Michael Schuepbach, Günther Deuschl, Thomas D. Hälbig, Tobias Wächter, Andreas Kupsch, Michael T. Barbe, Jan Vesper, Carmen Schade-Brittinger, Christine Brefel-Courbon, G.R. Fink, Jean-Luc Houeto, Friederike Sixel-Döring, Alireza Gharabaghi, Jens Volkmann, Karina Knudsen, David Maltête, Andrea A. Kühn, Andrea Falk, Patrick Mertens, Gerd-H. Schneider, Lars Timmermann, Alfons Schnitzler, Eric Seigneuret, Fabienne Ory-Magne, Pascal Derkinderen, Patrick Chaynes, Tatiana Witjas, Joern Rau, Valérie Fraix, S. Paschen, J. Regis, Lisa Tonder, Lars Wojtecki, Marcus O. Pinsker, Paul Krack, Haidar S. Dafsari, Andreas Hartmann, Fanny Pineau, Laura Paschen, Claudia Trenkwalder, Yves Agid, Universität Bern [Bern] (UNIBE), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), CIC AP-HP (pitie-Salpetriere)/inserm, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Medtronic [Minneapolis, MI, USA], Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], University of Geneva [Switzerland], Centre de coordination des essais cliniques, Philipps-University, Marburg, Allemagne., Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] (CIC Neurosciences), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), NeuroCure Clinical Research Center (NCRC), Charité University Medical Center, Charité (Campus Mitte), Berlin, Germany., Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Department of Neuroscience, Karolinska institutet, Stockholm, Sweden, Department of Neuroscience, Karolinska institutet, Department of Neurology, University Medical Center Schleswig-Holstein, Arnold-Heller-Street 3, Kiel 24105, Germany., Department of Neurology, Christian-Albrechts-University, Kiel, Germany., Christian-Albrechts-Universität zu Kiel (CAU), University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany., National Parkinson Foundation Centre of Excellence, King's College Hospital, London, UK., Department of Neurology, University of Cologne, Cologne, Germany., Department of Neurology, Movement Disorder and Neuromodulation Unit, Charité-Universitätsmedizin, Berlin, Germany., NeuroCure Clinical Research Center, Charité-Universitätsmedizin, Berlin, Germany., Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Department of Neurology & Neurosurgery, Charite University Medicine Berlin, Campus Virchow Klinikum & Benjamin Franklin, Berlin, Germany., Centre Hospitalier Universitaire [Grenoble] (CHU), Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), UM des troubles du mouvement, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service d'Anatomie et Cytopathologie [Toulouse], Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique de Toulouse (CIC 1436), Department of Functional Neurosurgery and Stereotaxy, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany., Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de neurologie [Rouen], Normandie Université (NU)-Normandie Université (NU), Clinique neurologique, Hôpital Laennec, Neuropathies du système nerveux entérique et pathologies digestives, implication des cellules gliales entériques, Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), Paracelsus-Elena-Klinik, Kassel, Germany., Department of Neurology, Philipps University Marburg, Germany., Paracelsus Elena Klinik, Centre for Parkinson's Disease & Movement Disorders, Department of Neurosurgery, University of Tuebingen, Center of Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, University of Vermont [Burlington], Stereotactic and Functional Neurosurgery Service and Gamma Knife Unit CHU Timone Marseille, France., AP-HM, CHU Timone, Pole de Neurosciences Cliniques, Department of Neurology, Marseille, France., Service de Neurologie, Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service Public de Wallonie, Department of Nuclear Medicine and PET Centre Aarhus University Hospital, Institute of Clinical Medicine Aarhus University, Norrebrogade 44, Building 10, 8000, Aarhus C, Denmark., Somnomar, Sleep Research Institute, Service de neurologie [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neurologie et thérapeutique expérimentale, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Heinrich-Heine-Universität Düsseldorf [Düsseldorf], Département de Neurologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-IFR70-CHU Pitié-Salpêtrière [APHP], Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Toulouse, Service de Pharmacologie Médicale et Clinique, CHU Toulouse [Toulouse], University of Vermont College of Medicine [Burlington, VT, USA], Laboratoire de Neurosciences Cognitives [Marseille] (LNC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR70-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Universität Bern [Bern], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Charité Hospital, Humboldt Universität zu Berlin, and Service de neurochirurgie [Rouen]
Subjects: 0301 basic medicine, medicine.medical_specialty, Parkinson's disease, Deep brain stimulation, medicine.medical_treatment, 610 Medicine & health, Disease, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Quality of life, Rating scale, law, Internal medicine, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Clinical endpoint, Medicine, ddc:610, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], 10. No inequality, ComputingMilieux_MISCELLANEOUS, business.industry, medicine.disease, humanities, 3. Good health, nervous system diseases, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], Subthalamic nucleus, 030104 developmental biology, Neurology (clinical), business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, 030217 neurology & neurosurgery
Abstract: ObjectiveTo investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications.MethodsWe performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson’s Disease Rating Scale (UPDRS) (UPDRS-III “off” and “on” medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI.ResultsPDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups (p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group.ConclusionImpaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS.Clinicaltrials.gov identifierNCT00354133.
Published: 2019
Full Text: View/download PDF

26. Stereotactic brain biopsy: evaluation of robot-assisted procedure in 60 patients

Author: Florent Marguet, Stéphane Derrey, Maxime Fontanilles, Laura Terrier, Vianney Gilard, Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de santé au travail et pathologie professionnelle [Rouen], Département d'oncologie médicale [Rouen], Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), and Normandie Université (NU)-Normandie Université (NU)
Subjects: Adult, Male, medicine.medical_specialty, Robot assisted, Stereotactic biopsy, Biopsy, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, 030218 nuclear medicine & medical imaging, Stereotaxic Techniques, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, medicine, Humans, Neuroradiology, medicine.diagnostic_test, business.industry, Brain Neoplasms, Brain biopsy, Mortality rate, Brain, Magnetic resonance imaging, Interventional radiology, Robotics, Middle Aged, 3. Good health, Oncology, Stereotactic, Surgery, Female, Neurology (clinical), Neurosurgery, Radiology, business, 030217 neurology & neurosurgery
Abstract: International audience; Background Frameless stereotactic biopsies, particularly robot-assisted procedures are increasing in neurosurgery centers.Results of these procedures should be at least equal to or greater than frame-based reference procedure. Evaluate robotassisted technology is necessary in particular, when a team has chosen to switch from one to another method.Objective The objective of our prospective work was (i) to evaluate the success rate of contributive robotic-assisted biopsy in 60patients, to report the morbidity and mortality associated with the procedure and (ii) to compare it with literature data.Methods We performed a prospective and descriptive study including 60 consecutive patients having had robotic-assistedstereotactic biopsy at the Rouen University Hospital, France. All patients had presurgical imaging before the procedure includedMagnetic Resonance Imaging merged with Computed Tomography scan acquisition. Registration was mostly performed with atouch-free laser (57/60). A control Computed Tomography scan was always realized at day 0 or day 1 after surgery. Datacollected were success rate, bleeding, clinical worsening, infection, and mortality.Results All the biopsies were considered as contributive and lead to the final diagnosis. In 41/60 patients (68%), the lesion wasglial. Six in 60 patients (10%) had visible bleeding without clinical worsening related, 5/60 patients (8.5%) showed clinicalimpairment following surgery, which was permanent in 2 patients, and 1/60 patient presented generalized seizures. We did notreport any infection and mortality.Conclusion Robot-assisted frameless surgery is efficient and provides a reasonable alternative to frame-based procedure. Theoperating time can be reduced, without increasing morbidity and mortality rates.
Published: 2019
Full Text: View/download PDF

27. Age Limits for Deep Brain Stimulation of Subthalamic Nuclei in Parkinson’s Disease

Author: Floriane Le Goff, Jean-Paul Bouwyn, Stéphane Derrey, Damien Fetter, David Maltête, Audrey Rouillé, Romain Lefaucheur, Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de neurochirurgie [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and UNIROUEN - UFR Santé (UNIROUEN UFR Santé)
Subjects: Male, medicine.medical_specialty, Deep brain stimulation, Parkinson's disease, medicine.medical_treatment, Audiology, Subthalamic nucleus, 03 medical and health sciences, Cellular and Molecular Neuroscience, Elderly, 0302 clinical medicine, Wisconsin Card Sorting Test, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], medicine, Humans, Verbal fluency test, Postoperative Period, 030212 general & internal medicine, Psychiatry, Aged, business.industry, Age Factors, Repeated measures design, Parkinson Disease, Cognition, Recovery of Function, Middle Aged, medicine.disease, Treatment Outcome, Parkinson’s disease, Neurology (clinical), business, 030217 neurology & neurosurgery, Stroop effect
Abstract: International audience; Background: Clinical pre-operative predictive factors of optimal STN-DBS motor outcome in Parkinson’s disease (PD) have been previously reported. However, available data involving elderly patients are conflicting. Objective: To compare early post-operative outcomes in parkinsonian patients younger than 65 years old (group 1) vs patients 65 years old or older (group 2) at the time of surgery. Methods: The cognitive and motor effects of DBS were evaluated by comparison of different scores obtained before (baseline) and 6 months after surgery using a repeated measures analysis of variance. Results: Post-operative motor improvement (UPDRS part III and UPDRS part IV scores) and drug reduction were not statistically different between groups 1 and 2 (P > 0.05). Axial motor score which was significantly worse in group 2 in the on-drug condition before surgery was also significantly worse both in off-drug/on-stimulation and on-drug/on-stimulation conditions (P
Published: 2016
Full Text: View/download PDF

28. 371MO Usefulness of circulating tumour DNA detection from cerebrospinal fluid in recurrent high-grade glioma

Author: Nicolas Magne, Ludivine Beaussire, Annie Laquerrière, A. Deniel, Florent Marguet, N. Sarafan Vasseur, Stéphane Derrey, F. Di Fiore, M. Fontanilles, Cristina Alexandru, Florian Clatot, and Doriane Richard
Subjects: Dna detection, Pathology, medicine.medical_specialty, Cerebrospinal fluid, Oncology, business.industry, Medicine, Hematology, business, High-Grade Glioma
Published: 2020
Full Text: View/download PDF

29. External ventricular drainage for intracranial hypertension syndrome complicating influenza-associated encephalitis

Author: Zoé Demailly, Hélène Braud, Stéphane Derrey, Adeline Baron, Isabelle Gueit, François Caron, Bertrand Dureuil, and Vianney Gilard
Subjects: medicine.medical_specialty, business.industry, Treatment outcome, Ventricular drainage, Intracranial hypertension syndrome, medicine.disease, X ray computed, medicine, Surgery, Neurology (clinical), Radiology, Drainage, business, Encephalitis
Published: 2020
Full Text: View/download PDF

30. Does Bilateral Deep Brain Stimulation of the Subthalamic Nucleus Modify Ano-Rectal Motility in Parkinson's Disease? Results of a Randomized Cross-Over Study

Author: David Maltête, Guillaume Gourcerol, Stéphane Derrey, Marie-Laure Welter, Anne Marie Leroi, Nathalie Chastan, Service de physiologie digestive, urinaire, respiratoire et de l'exercice [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service de neurologie [Rouen], CHU Rouen, Service de neurophysiologie [Rouen], Mobilités : Vieillissement, Pathologie, Santé (COMETE), Université de Caen Normandie (UNICAEN), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurochirurgie [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Caen Normandie (UNICAEN), and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Adult, Male, medicine.medical_specialty, Constipation, Deep brain stimulation, Parkinson's disease, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Deep Brain Stimulation, Urology, [SHS.PSY]Humanities and Social Sciences/Psychology, Anal Canal, Proof of Concept Study, Dyssynergia, 03 medical and health sciences, 0302 clinical medicine, Subthalamic Nucleus, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Aged, Cross-Over Studies, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Rectum, Parkinson Disease, General Medicine, Middle Aged, medicine.disease, Crossover study, nervous system diseases, Subthalamic nucleus, surgical procedures, operative, Anesthesiology and Pain Medicine, nervous system, Neurology, Reflex, Defecation, Female, Neurology (clinical), medicine.symptom, business, Gastrointestinal Motility, therapeutics, 030217 neurology & neurosurgery
Abstract: Background Ano-rectal motility impairment is often observed during Parkinson's disease (PD), generating symptoms as constipation and/or incontinence with impaired quality of life. Subthalamic nuclei (STN) deep brain stimulation (DBS) improves motor symptoms of PD, but its effects on anorectal motility are unknown. This study aimed to assess the effects of STN-DBS on the anorectal motility in PD patients, in a randomized cross-over study. Methods Sixteen PD patients with bilateral STN-DBS for at least 6 months were included. The anal resting pressure, duration and maximal amplitude of squeeze effort, recto-anal inhibitory reflex, maximal tolerable rectal volume, and anal pressure during defecation effort were measured and compared after STN-DBS was switched OFF and then ON for 2 hours, or vice-versa, in a randomized order. Key results STN-DBS increased maximal amplitude of anal squeezing pressure (OFF: 85.7 ± 14.5 vs ON: 108.4 ± 21.0 cmH2 O; P = 0.02), with no significant difference in the duration (P = 0.10). No other significant difference was found between stimulation conditions (OFF vs ON) for anal resting pressure (OFF: 72.5 ± 8.6 cmH2 O vs ON: 71.7 ± 9.0 cmH2 O; P = 0.24), recto-anal inhibitory reflex, maximal tolerable rectal volume (OFF: 231 ± 24 mL vs ON: 241 ± 26 mL; P = 0.68), or anal pressure during defecation effort with a similar rate of ano-rectal dyssynergia (7/16 and 8/16 with and without STN-DBS, respectively). No order effect (ON-OFF vs OFF-ON) was observed. Conclusion and inferences STN-DBS increased anal squeezing pressure, but did not modify anorectal dyssynergia in PD patients, This study demonstrated the involvement of STN in the voluntary control of anorectal motility in PD patients.
Published: 2018
Full Text: View/download PDF

31. Spinal meningioma and factors predictive of post-operative deterioration

Author: Stéphane Derrey, Florent Marguet, Alexis Perez, Vianney Gilard, Olivier Langlois, Alice Goia, Nicolas Magné, François-Xavier Ferracci, Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Radiologie [CHU Rouen], Normandie Université (NU)-Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and UNIROUEN - UFR Santé (UNIROUEN UFR Santé)
Subjects: Male, Cancer Research, Neurology, medicine.medical_treatment, Neurosurgical Procedures, 0302 clinical medicine, Postoperative Complications, Risk Factors, Meningeal Neoplasms, Medicine, Post operative, Extramedullary, Aged, 80 and over, MESH: Laminectomy/adverse effects, Meningeal Neoplasms/pathology, Meningeal Neoplasms/surgery, Nervous System Diseases/etiology, Neurosurgical Procedures/adverse effects, Laminectomy, Middle Aged, 3. Good health, medicine.anatomical_structure, Treatment Outcome, Oncology, Spinal Cord, 030220 oncology & carcinogenesis, Predictive value of tests, Female, Meningioma, medicine.medical_specialty, Spinal meningioma, Prognostic factors, Spinal tumor, 03 medical and health sciences, Predictive Value of Tests, Intradural, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Aged, Retrospective Studies, Surgical outcome, business.industry, Retrospective cohort study, medicine.disease, Spinal cord, Surgery, Relative risk, Neurology (clinical), Nervous System Diseases, business, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract: International audience; PURPOSE:Spinal meningiomas are slow-growing intradural-extramedullary tumors. They are usually associated with good outcomes. However, there are few descriptions of factors predictive of impaired evolution. Our objective was to identify predictive factors of post-operative deterioration as well as outcomes at follow-up.METHODS:Between 2009 and 2016, 87 patients had surgery for spinal meningioma in our referral center. Clinical presentation, management and outcomes were reported during the post-operative period and at 3-month follow-up. Evaluation was based on post-operative neurological deterioration defined as an increase of at least one point in the McCormick score compared to the status at admission.RESULTS:During the study period, post-operative deterioration occurred in 17 patients (19.5%). Risk factors associated with this deterioration were the absence of pre-operative neurological signs (Relative Risk; RR = 2.38, p = 0.04), an anterior location of the meningioma and a grade 2 meningioma on WHO classification score (RR = 6, p ≤ 0.01). At 3-month follow-up, in patients who initially presented with a motor deficit, partial recovery was found in 75%, stability in 20% and a deterioration of their clinical status in 5%. After a mean follow-up of 92.4 ± 51.9 months, the recurrence rate was 8%.CONCLUSIONS:Spinal meningiomas are usually benign tumors whose treatment is based on complete surgical resection. Progress in surgical techniques has resulted in lower morbidity rates and improvement in post-operative recovery. In this study, we observed several factors associated with clinical deterioration. Before surgery, patients should be fully informed of these predictive factors of post-operative deterioration and their association with surgical morbidity.
Published: 2018
Full Text: View/download PDF

32. Sudden paraplegia due to spontaneous bleeding in a thoracic epidural angiolipoma and literature review

Author: M. Lacour, Stéphane Derrey, S. Curey, V. Gilard, Florent Marguet, A. Perez, Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de neurochirurgie [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de santé au travail et pathologie professionnelle [Rouen], Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), and UNIROUEN - UFR Santé (UNIROUEN UFR Santé)
Subjects: Male, medicine.medical_specialty, Adolescent, Angiolipoma, medicine.medical_treatment, Hemorrhage, Thoracic Vertebrae, Lesion, 03 medical and health sciences, 0302 clinical medicine, Spinal cord compression, medicine, Humans, Medical history, Spinal cord compression Epidural haematoma, Paraplegia, business.industry, Laminectomy, medicine.disease, Spinal cord, 3. Good health, Surgery, medicine.anatomical_structure, 030220 oncology & carcinogenesis, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Epidural Neoplasms, Neurology (clinical), Presentation (obstetrics), medicine.symptom, business, Epidural spinal tumour, Spinal Cord Compression, 030217 neurology & neurosurgery
Abstract: International audience; Background. Spinal angiolipomas are rare epidural tumours that are usually revealed by chronic symptoms of medullar irritation. We report a case of acute paraplegia caused by spontaneous bleeding revealing a thoracic angiolipoma.Case description. A 17-year-old male patient with no previous medical history was admitted for acute onset of paraplegia with bladder retention and loss of sensation in the lower limbs, preceded by dorsal pain during the three previous days. MRI showed an enhanced T1-weighted image of a T7–T12 epidural lesion. The T1-weighted isosignal and the T2-weighted hyposignal suggested haemorrhagic complications. Due to a mass effect on the spinal cord, an emergency laminectomy was performed. Histopathological examination of the lesion revealed an angiolipoma with spontaneous bleeding. Clinical outcome was favourable after two months.Conclusion. This case is one of the first to be reported, although the clinical presentation is similar to that of other rare reported cases of paraplegia due to spinal compression by tumoural bleeding.
Published: 2018
Full Text: View/download PDF

33. Giant intracranial aneurysms in the paediatric population: Suggested management and a review of the literature

Author: François Proust, Hélène Castel, Stéphane Derrey, A.-S. Pruvot, S. Curey, Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), and Différenciation et communication neuronale et neuroendocrine (DC2N)
Subjects: Pediatrics, medicine.medical_specialty, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Neurosurgical Procedures, 030218 nuclear medicine & medical imaging, MASS syndrome, 03 medical and health sciences, 0302 clinical medicine, Aneurysm, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Medicine, cardiovascular diseases, Clinical decision, Endovascular coiling, Cerebral Revascularization, business.industry, Female sex, Intracranial Aneurysm, medicine.disease, Embolization, Therapeutic, Microsurgical treatment, Cerebral Angiography, 3. Good health, Treatment Outcome, cardiovascular system, Surgery, Neurology (clinical), Presentation (obstetrics), business, 030217 neurology & neurosurgery, Paediatric population
Abstract: International audience; ObjectivesIntracranial aneurysms are rare in children although giant aneurysms more commonly occur in adolescence. The aims of our study were to perform an extensive review of the literature over the past two decades and assess intracranial aneurysm management.MethodsBased on a Pubmed search, we carried out a review of the literature from 1990 to 2012 regarding giant intracranial aneurysms diagnosed in the paediatric population. This descriptive study concerned clinical presentation, cerebral aneurysm characteristics, therapeutic management procedures and outcome.ResultsForty-six cases were reported in 31 papers. The male/female sex ratio was 1.15, the clinical presentation was a tumour mass syndrome in 56.6%, followed by rupture in 30.4%. The aneurysm location was the posterior circulation in 41.3%, and microsurgical treatment (52.2%) predominated over endovascular coiling (28.3%).ConclusionTo date, no evidence-based medicine recommendation has been accepted for the management of rare intracranial aneurysms. Each reported patient was the object of a multidisciplinary clinical decision. Management of this challenging pathology should be performed on a case-to-case basis.; Les anévrismes géants de l’enfant, exceptionnels, sont rapportés uniquement sous forme d’observations. L’objectif de ce travail était de réaliser une revue exhaustive des publications sur le sujet afin de mieux définir cette situation clinique qui constitue un challenge thérapeutique.
Published: 2016
Full Text: View/download PDF

34. French collaborative group series on giant intracranial aneurysms: Current management

Author: J. Laguarrigue, M. Lonjon, Vincent Lubrano, Laurent Thines, François Proust, Evelyne Emery, Damien Bresson, Guillaume Penchet, Jean-Paul Lejeune, Stéphane Derrey, B. Irthum, P. David, B. Bataille, and I. Pelissou
Subjects: Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Nice, Young Adult, Collaborative group, Modified Rankin Scale, Humans, Medicine, Endovascular treatment, Aged, Retrospective Studies, computer.programming_language, Surgical team, Endovascular coiling, business.industry, Intracranial Aneurysm, Middle Aged, Neurovascular bundle, Surgery, Treatment Outcome, Current management, Female, France, Neurology (clinical), business, computer
Abstract: Giant intracranial aneurysms represent a major therapeutic challenge for each surgical team. The aim of our study was to extensively review the French contemporary experience in treating giant intracranial aneurysms in order to assess the current management.This retrospective multicenter study concerned consecutive patients treated for giant intracranial aneurysms (2004-2008) in different French university hospitals (Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Nice, Paris-Lariboisière, Rouen et Toulouse). Different variables were analyzed: the diagnostic circumstances, the initial clinical status based on the WFNS scale, aneurysmal features and exclusion procedure. At 6 months, the outcome was evaluated according to the modified Rankin Scale (mRS): favorable (mRS 0-2) and unfavorable (mRS 3-6). A multivariate logistic regression model included all the independent variables with P0.25 in the univariate analysis (P0.05).A total of 79 patients with a mean age of 51.5 ± 1.6 years (median: 52 years; range: 16-79) were divided into two groups, with the ruptured group (n=26, 32.9%) significantly younger (P0.05, Student's-t-test) than the unruptured group (n=53, 67.1%). After SAH, the initial clinical status was good in 12 patients (46.2%), and in the unruptured group, the predominant diagnosis circumstance was a pseudo-tumor syndrome occurring in 22 (41.5%). The first procedure of aneurysm treatment in the global population was endovascular in 42 patients (53.1%), microsurgical in 29 (36.7%) and conservative in 8 (10.2). An immediate neurological deterioration was reported in 38 patients (48.1%) after endovascular treatment in 19 (45.2% of endovascular procedures), after miscrosurgical in 15 (51.7% of microsurgical procedures) and after conservative in 4 (the half). At 6 months, the outcome was favorable in 45 patients (57%) and after multivariate analysis, the predictive factors of favorable outcome after management of giant cerebral aneurysm were the initial good clinical status in cases of SAH (P0.002), the endovascular treatment (P0.005), and the absence of neurological deterioration (P0.006). The endovascular procedure was obtained as a predictive factor because of the low risk efficacy of indirect procedures, in particular a parent vessel occlusion.The overall favorable outcome rate concerned 57% of patients at 6 months despite 53.8% of poor initial clinical status in cases of rupture. The predictive factors for favorable outcome were good clinical status, endovascular treatment and the absence of postoperative neurological deterioration. Endovascular treatment should be integrated into the therapeutic armenmatarium against giant cerebral aneurysms but the durability of exclusion should be taken into account during the multidisciplinary discussion by the neurovascular team.
Published: 2015
Full Text: View/download PDF

35. Impact of deep brain stimulation on pharyngo-esophageal motility: a randomized cross-over study

Author: Pierre Fréger, Anne-Marie Leroi, Jacques Weber, François Proust, Nathalie Chastan, Romain Lefaucheur, David Maltête, Eric Verin, Stéphane Derrey, Pierre Déchelotte, Guillaume Gourcerol, Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Mobilités : Vieillissement, Pathologie, Santé (COMETE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Service de neurologie [Rouen], CHU Rouen, Service de physiologie digestive, urinaire, respiratoire et de l'exercice [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Pathology Department, Ippokration Hospital, Service de neurochirurgie [CHU Rouen], Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Normandie Université (NU)-Hôpital Charles Nicolle [Rouen], Service de nutrition [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Service de neurophysiologie [Rouen]
Subjects: Male, Deep brain stimulation, Parkinson's disease, Manometry, Physiology, Deep Brain Stimulation, [SDV]Life Sciences [q-bio], medicine.medical_treatment, [SHS.PSY]Humanities and Social Sciences/Psychology, Stimulation, Contractility, 03 medical and health sciences, Esophagus, 0302 clinical medicine, Subthalamic Nucleus, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], medicine, Humans, High resolution manometry, ComputingMilieux_MISCELLANEOUS, Aged, Cross-Over Studies, Endocrine and Autonomic Systems, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Gastroenterology, Parkinson Disease, Middle Aged, medicine.disease, Crossover study, Subthalamic nucleus, Treatment Outcome, Anesthesia, Pharynx, Cholinergic, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, 030211 gastroenterology & hepatology, Gastrointestinal Motility, business, 030217 neurology & neurosurgery
Abstract: Background Bilateral subthalamic nucleus (STN) stimulation is used to alleviate Parkinson's disease (PD) motor symptoms. Recently, it has been shown that this therapeutic also increased gut cholinergic contractions. We therefore investigated the effect of STN stimulation on esophageal motility in an interventional randomized study. Methods Sixteen humans PD patients (4 women, 12 men; age: 62.4 ± 9.3-years old) who underwent STN stimulation for at least 6 months were randomly evaluated with either stimulator turned OFF then ON, or inversely. Esophageal high resolution manometry was performed at the end of each ON and OFF period, with a 5 min resting period followed by ten swallows of 5 mL. Key Results During the ON, an increase in the distal contractility index was found (OFF: 1750 ± 629 vs ON: 2171 ± 755 mmHg/cm/s; p = 0.03), with no difference in the distal front velocity. A decrease in the integrative relaxation pressure of the lower esophageal sphincter (LES) was noted (OFF: 11.1 ± 1.8 mmHg vs ON: 7.2 ± 1.8 mmHg; p
Published: 2015
Full Text: View/download PDF

36. Surgical technique

Author: Marc Guénot, Axel Lebas, Bertrand Devaux, Sophie Colnat-Coulbois, Georg Dorfmuller, Aileen McGonigal, Nicolas Reyns, Vianney Gilard, Stéphane Derrey, Jean-Christophe Sol, Stéphane Clémenceau, Neurosurgery, Hospices Civils de Lyon (HCL), Service de neurophysiologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Université Paris Descartes - Paris 5 (UPD5), Service de Neurochirurgie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de neurochirurgie pédiatrique [Fondation Rothschild, Paris], Fondation Rothschild, Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Neurochirurgie[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Service de neurochirurgie [CHU Rouen], Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de neurochirurgie [Rouen], and CHU Pitié-Salpêtrière [APHP]
Subjects: Age Factors, Brain, Electroencephalography, Neuroimaging, General Medicine, Magnetic Resonance Imaging, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], Electrodes, Implanted, 03 medical and health sciences, 0302 clinical medicine, Neurology, 030220 oncology & carcinogenesis, Physiology (medical), [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Humans, Neurology (clinical), [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, 030217 neurology & neurosurgery, ComputingMilieux_MISCELLANEOUS
Abstract: In SEEG, as for any surgical procedure, the benefit/risk ratio is a key-point. This implies rigorous clinical practice in terms of indication, information delivered to the patient, and surgical technique. Numerous technical options may be used to achieve this goal. All are valuable, as long as they are executed with rigor and consistency. Intracranial bleeding represents the main risk of the procedure (1-4% of cases). The procedure also carries a risk of infection (0.8%), death (total of 6 reported cases in all the literature,0.002%), and of minor and transient side effects. SEEG is performed under general anesthesia. MRI is the gold standard morphological imaging, used for targeting and for trajectory calculations. It is strictly necessary to use some form of vascular imaging to minimize the peroperative bleeding risk. SEEG can be performed on a frame-based, or frameless, basis, using stereotactic instrumentation, or a neurosurgical robot. Literature does not provide any data in favour of one of these techniques compared to the other. The minimal acceptable bone thickness is considered to be 2mm. Postoperatively, as soon as any non-preexisting neurological deficit is noticed, neuroimaging must immediately be performed. It is recommended to perform a postoperative imaging during the 24hours after implantation. The numerous current possibilities, in terms of imaging and technology, give rise to many possible stereotactic strategies for performing SEEG implantation. None of these strategies can be considered as superior to the other. The guarantee of the best possible result is provided by the care with which these procedures are done.
Published: 2018
Full Text: View/download PDF

37. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma

Author: Fabrice Jardin, Hervé Tilly, Elodie Bohers, Annie Laquerrière, Maxime Fontanilles, Florent Marguet, Catherine Maingonnat, Jean Michel Picquenot, Stéphane Derrey, Sylvain Mareschal, Elena Liana Veresezan, Pierre-Julien Viailly, Philippe Bertrand, Sydney Dubois, Vincent Camus, Philippe Ruminy, Stéphane Leprêtre, Laboratoire d'hématologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Pathology, Rouen University Hospital, Service d'Hématologie Becquerel, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Département de Pathologie [CHU Rouen], Service de neurochirurgie [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), and Service d'Anatomie et Cytologie Pathologique [CHU Rouen]
Subjects: 0301 basic medicine, Oncology, Male, Pathology, Lymphoma, Biopsy, [SDV]Life Sciences [q-bio], DNA Mutational Analysis, Central Nervous System Neoplasms, circulating cell-free tumor DNA, 0302 clinical medicine, Gene Frequency, somatic mutation, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, Primary central nervous system lymphoma, High-Throughput Nucleotide Sequencing, DNA, Neoplasm, Genomics, Middle Aged, Magnetic Resonance Imaging, 3. Good health, 030220 oncology & carcinogenesis, Female, DNA, Circular, Personal genomics, Research Paper, medicine.medical_specialty, Sensitivity and Specificity, DNA sequencing, 03 medical and health sciences, Germline mutation, Internal medicine, medicine, Humans, Liquid biopsy, Alleles, Aged, primary central nervous system lymphoma, liquid biopsy, business.industry, Cancer, Ion semiconductor sequencing, medicine.disease, 030104 developmental biology, Case-Control Studies, Mutation, next-generation sequencing, Personalized medicine, business
Abstract: // Maxime Fontanilles 1, 2 , Florent Marguet 3, 4 , Elodie Bohers 2 , Pierre-Julien Viailly 2 , Sydney Dubois 2 , Philippe Bertrand 2 , Vincent Camus 1, 2 , Sylvain Mareschal 2 , Philippe Ruminy 2 , Catherine Maingonnat 2 , Stephane Lepretre 1 , Elena-Liana Veresezan 5 , Stephane Derrey 6 , Herve Tilly 1, 2 , Jean-Michel Picquenot 5 , Annie Laquerriere 3, 4 and Fabrice Jardin 1, 2 1 Department of Hematology, Cancer Center Henri Becquerel, 76000 Rouen, France 2 INSERM U1245, Cancer Center Henri Becquerel, Institute of Research and Innovation in Biomedicine (IRIB), University of Normandy, UNIVROUEN, 76000 Rouen, France 3 INSERM U1245 and Hopital Charles Nicolle, NeoVasc Team, University of Normandy, UNIVROUEN, CHU-Hopitaux de Rouen, 76031 Rouen, France 4 Department of Neuropathology, Hopital Charles Nicolle, Normandy Center for Genomic and Personalized Medicine, CHU-Hopitaux de Rouen, 76031 Rouen, France 5 Department of Pathology, Cancer Center Henri Becquerel, 76000 Rouen, France 6 Department of Neurosurgery, Hopital Charles Nicolle, CHU-Hopitaux de Rouen, 76031 Rouen, France Correspondence to: Fabrice Jardin, email: fabrice.jardin@chb.unicancer.fr Keywords: primary central nervous system lymphoma, circulating cell-free tumor DNA, somatic mutation, liquid biopsy, next-generation sequencing Received: March 08, 2017 Accepted: May 03, 2017 Published: June 01, 2017 ABSTRACT Purpose: Primary central nervous system lymphomas (PCNSL) have recurrent genomic alterations. The main objective of our study was to demonstrate that targeted sequencing of circulating cell-free DNA (cfDNA) released by PCNSL at the time of diagnosis could identify somatic mutations by next-generation sequencing (NGS). Patients and Methods: PlasmacfDNA and matched tumor DNA (tDNA) from 25 PCNSL patients were sequenced using an Ion Torrent Personal Genome Machine (Life Technologies ® ). First, patient-specific targeted sequencing of identified somatic mutations in tDNA was performed. Then, a second sequencing targeting MYD88 c.T778C was performed and compared to plasma samples from 25 age-matched control patients suffering from other types of cancer. Results: According to the patient-specific targeted sequencing, eight patients (32% [95% CI 15-54%]) had detectable somatic mutations in cfDNA. Considering MYD88 sequencing, six patients had the specific c.T778C alteration detected in plasma. Using a control group, the sensitivity was 24% [9-45%] and the specificity was 100%. Tumor volume or deep brain structure involvement did not influence the detection of somatic mutations in plasma. Conclusion: This pilot study provided evidence that somatic mutations can be detected by NGS in the cfDNA of a subset of patients suffering from PCNSL.
Published: 2017
Full Text: View/download PDF

38. Comparison of electromagnetic neuronavigation system and free-hand method for ventricular catheter placement in internal shunt

Author: Pierre Hannequin, Stéphane Derrey, Nicolas Magne, Vianney Gilard, Valérie Pelletier, S. Curey, Emmanuel Gerardin, Endothélium microcirculatoire cérébral et lésions du système nerveux central au cours du développement (Néovasc), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Radiologie [CHU Rouen], Normandie Université (NU)-Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pharmacie [CHU Rouen], Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), and Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Adult, Male, Neuronavigation system, medicine.medical_specialty, Neuronavigation, Catheter Obstruction, Ventriculoperitoneal Shunt, 03 medical and health sciences, Electromagnetic Fields, 0302 clinical medicine, medicine, Humans, Longitudinal Studies, ComputingMilieux_MISCELLANEOUS, Aged, business.industry, General Medicine, Middle Aged, medicine.disease, Ventricular catheter, Hydrocephalus, Surgery, Shunt (medical), Catheter, Outcome and Process Assessment, Health Care, medicine.anatomical_structure, Ventricle, 030220 oncology & carcinogenesis, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Neurology (clinical), Radiology, business, 030217 neurology & neurosurgery
Abstract: Objective Optimal ventricular catheter positioning is able to reduce the risk of catheter dysfunction, and subsequently the risk of multiple revision surgery. The objective of our study was to compare the proportion of optimal ventricular catheter placements in a cohort of patients operated for ventriculoperitoneal (VP) shunt between a free-hand group and a neuronavigated group. Patients and methods Twenty patients with hydrocephalus requiring VP shunt were prospectively included in this study. Patients were divided into two groups; the ventricular catheter was positioned using free-hand method (n = 10) or magnetic navigation system (n = 10). For the two groups, clinical baseline characteristics, etiology of hydrocephaly and initial ventricular size were assessed. The main judgment criterion was the proportion of optimal catheter placements defined by the presence of all catheter holes in the ventricle, evaluated on post-operative CT scan. Results There was no initial difference between the two groups in terms of hydrocephalus etiology or initial ventricular size. The number of optimal catheter placements was 6/10 in the neuronavigated group versus 1/10 in the free-hand group (p Conclusion In patients suffering from hydrocephaly, the use of an electromagnetic neuronavigation system for ventricular catheter placement significantly improved the proportion of optimal catheter placements. Long-term follow-up is necessary to evaluate the number of revision surgeries and the cost in each group.
Published: 2017
Full Text: View/download PDF

39. Symptomatic cervical myelopathy due to general dystonia: Case report and review of the literature

Author: Stéphane Derrey, David Maltête, Lou Grangeon, A. Perez, V. Gilard, Romain Lefaucheur, Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de neurologie [Rouen], Normandie Université (NU)-Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and UNIROUEN - UFR Santé (UNIROUEN UFR Santé)
Subjects: Dystonia, Pediatrics, medicine.medical_specialty, business.industry, medicine.disease, 3. Good health, Surgery, 03 medical and health sciences, Myelopathy, 0302 clinical medicine, Text mining, Neurology, medicine, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], 030212 general & internal medicine, Neurology (clinical), business, 030217 neurology & neurosurgery, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2017
Full Text: View/download PDF

40. Non-motor fluctuations in Parkinson's disease: Prevalence, characteristics and management in a large cohort of parkinsonian outpatients

Author: Lucile Brun, David Wallon, Damien Fetter, Stéphane Derrey, Romain Lefaucheur, Alaina Borden, Bertrand Bourre, and David Maltête
Subjects: Male, Pediatrics, medicine.medical_specialty, Parkinson's disease, Disease duration, Primary Dysautonomias, Disease, Antiparkinson Agents, Levodopa, medicine, Humans, Sensory symptoms, Aged, Movement Disorders, business.industry, Age Factors, Dysautonomia, Parkinson Disease, Mean age, General Medicine, Middle Aged, medicine.disease, Large cohort, Cross-Sectional Studies, Physical therapy, Non motor, Female, Surgery, Neurology (clinical), medicine.symptom, business, Case Management
Abstract: Objective To describe demographic and clinical characteristics in a group of Parkinson's disease (PD) patients with non-motor fluctuations (NMF) and to evaluate the management of medications proposed to treat NMF. Methods Three hundred and three PD patients (mean age, 66±10.3 years; mean disease duration, 10.1±6.5 years) were enrolled. Each patient was interviewed in a non-directed fashion about the main NMF manifestations, i.e. dysautonomic, mental, and sensory symptoms. Both groups of patients with and without NMF were compared. Dysautonomia, motor fluctuations, age, disease duration, and LEDD were included in a multiple regression to determine which were predictive of NMF. Results NMF were found in 57 (19%) patients, mean age 65±10.1 years, mean age at onset of PD 53.7±10.9 years, mean disease duration 12.5±6.9 years. NMF occurred on average 9.8±7.7 years after the onset of PD. Fifty patients (86%) with NMF had also MF and 10 (21%) had PDD. Twenty-five (44%) patients suffered from sensory, 28 (49%) from autonomic and 25 (44%) from neuropsychiatric symptoms. Both disease and l-Dopa treatment durations, and LEDD were significantly higher in NMF patient's group. Motor fluctuations ( p =0.0016) and presence of dysautonomia ( p =0.007) were found to be two independent predictors of NMF. Conclusion The development of new instruments to assess NMF is crucial for optimized management of advanced PD.
Published: 2014
Full Text: View/download PDF

41. Les lésions postérieures du troisième ventricule et de la lame tectale chez les enfants : quelle est la meilleure stratégie ? Expérience Normande

Author: O. Langlois, Stéphane Derrey, Evelyne Emery, V. Gilard, F. Villedieu, and Alin Borha
Subjects: Surgery, Neurology (clinical)
Abstract: Introduction Les lesions de la partie posterieure du 3e ventricule (V3) et de la region tectale sont des lesions rares et representent un challenge pour le neurochirurgien. Le but de l’etude est d’analyser la prise en charge, les techniques operatoires ainsi que les resultats d’une population pediatrique des deux services de neurochirurgie normands (Caen–Rouen). Materiel et methodes Nous avons analyse d’une facon retrospective les patients (âge Quinze patients ont ete pris en charge sur la periode etudiee. Il y avait 9 patients de sexe masculin et 6 de sexe feminin. L’âge moyen des patients au diagnostic etait de 10 ans (0,8–17). Le contexte de decouverte de ces lesions etait : un syndrome d’hypertension intracrânienne (HTIC) avec une hydrocephalie dans 11 cas, un syndrome d’HTIC avec paresthesies et hemiparesie dans un cas, des cephalees isolees persistantes dans 3 cas. Cinq patients ont eu une biopsie en premiere intention. Onze interventions chirurgicales ont ete realisees pendant la prise en charge : 3 par voie interhemispherique transforaminale, 3 par voie supra cerebelleuse infratentorielle, 3 par voie interhemispherique sous occipitale transtentorielle, une par voie interhemispherique transcalleuse posterieure et une par voie trans parietale. Resultats Les resultats anatomopathologiques etaient en faveur d’une tumeur de la ligne germinale dans 3 cas, tumeurs benignes de la ligne astrocytaire (3 cas), pinealoblastome (1 cas), glioblastome (1 cas), tumeur teratoide rhabdoide atypique ATRT (1 cas), medulloblastome (1 cas), tumeur primitive neuroectodermique (1 cas), et un kyste neuroepithelial dans 2 cas. 2 cas ont ete simplement suivi pour leur lesions. L’hydrocephalie a ete prise en charge par technique endoscopique dans 10 cas. Aucune mortalite ou morbidite severe en postoperatoire immediat n’a ete observee. Le suivi moyen etait de 20 mois (3 mois et 5 ans). Deux patients avec des tumeurs malignes sont decedes lors du suivi, a environ deux ans apres le diagnostic. Conclusion Les lesions de la partie posterieure du troisieme ventricule sont decouvertes surtout dans un contexte d’hydrocephalie et hypertension intracrânienne qui est bien controlee par une ventriculocisternostomie. L’etiologie anatomopathologique est variee mais avec une predominance germinale ou astrocytaire. La chirurgie par voie d’abord supratentorielle inter hemispherique reste la voie preferentielle pour aborder ces lesions si la resection est decidee.
Published: 2019
Full Text: View/download PDF

42. Brain metastasis from renal cell carcinoma

Author: Hélène Castel, O Bennani, Stéphane Derrey, Annie Laquerrière, François Proust, O. Langlois, and Pierre Fréger
Subjects: Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Disease, Radiosurgery, Gastroenterology, Metastasis, Renal cell carcinoma, Internal medicine, medicine, Humans, Carcinoma, Renal Cell, Aged, Retrospective Studies, Univariate analysis, Brain Neoplasms, business.industry, Histology, Patient survival, Middle Aged, Prognosis, medicine.disease, Kidney Neoplasms, Surgery, Female, Neurology (clinical), Neoplasm Recurrence, Local, business, Brain metastasis
Abstract: Background Patients with brain metastasis (BM) from renal cell carcinoma (RCC) have a poorly known prognosis due to the rarity of this disease. The aim of our study was to assess the outcome of patients with a BM due to RCC, and to determine the predictive factors for survival. Methods Consecutive patients who underwent treatment between 1997 and 2012 were identified retrospectively from a database (n = 28, median age of 57.8 years, sex ratio M/F: 3.7). Main criteria collected concerned survival time. Other data collected were relative to initial histology, clinical findings at the time of BM diagnosis (diagnosis circumstances, KPS), radiological findings and BM characteristics (number, size and localization), treatment of BM (including surgery, stereotactic radiosurgery [SRS], systemic treatments, whole brain radiotherapy [WBRT]) and the outcome of surgery if performed. Statistical analysis of survival was performed using the Kaplan-Meier method. Results Median survival was 13.3 months, 1-year survival was 60.2%, 2-year survival was 16.4%. Univariate analysis showed the existence of intracranial hypertension (P = 0.01), other systemic metastasis (P = 0.049), the absence of deep metastasis (P = 0.03) which are all linked to shorter survival. Age, KPS, initial histology of RCC, number, size, localization, and hemorrhage in BM were not correlated to survival. The median survival in the surgical resection group was 25.3 months versus 8.6 months (P = 0.02). The main criteria for the selection of the surgical group were a single BM (P = 0.04), and superficial metastasis (P = 0.02). Conclusions Three predictive factors for longer survival in BMRCC were the absence of intracranial hypertension, the absence of acute metastasis and the absence of extracranial metastasis. Surgical removal, when possible, seems to benefit patient survival.
Published: 2014
Full Text: View/download PDF

43. Traitements locorégionaux des sites métastatiques chez des patients atteints d’un mélanome pauci-métastatique (hors métastase cérébrale) : recommandations nationales françaises

Author: A. Mourregot, Bruno Sassolas, Inna Dygai-Cochet, Patrick Combemale, Marie-Thérèse Leccia, Olivier Tiffet, Sophie Siegrist, Laetitia Verdoni, Xavier Mirabel, Stéphane Derrey, François Planchamp, Gilles Truc, Christophe Bedane, Vincent Lubrano, Didier Cupissol, Philippe Modiano, Valérie Mazeau-Woynar, Marie-Eve Rougé-Bugat, Laurence Lamant, and Juliette Thariat
Subjects: Gynecology, Cancer Research, medicine.medical_specialty, Metastatic Cutaneous Melanoma, Oncology, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, General Medicine, business
Abstract: Resume Introduction ces dernieres annees ont ete marquees par l’emergence de nouvelles molecules pour le traitement des formes metastatiques avec un benefice significatif sur la survie des patients. Par ailleurs, de nombreuses techniques sont developpees actuellement pour le traitement locoregional des sites metastatiques, apportant ainsi de nouvelles perspectives therapeutiques. Toutefois, la mise a disposition de ces nouveaux traitements souleve aupres des professionnels de sante des interrogations quant a leur utilisation et place dans la strategie therapeutique. Objectif l’Institut national du cancer, dont l’une des missions est de definir et de favoriser la diffusion de recommandations nationales de bonnes pratiques cliniques depuis 2008, a souhaite diffuser un etat des lieux des connaissances sur ces modalites de traitement et formuler des recommandations afin de permettre une diffusion au niveau national de l’innovation tout en favorisant son bon usage. Methode le processus d’elaboration est base sur une revue systematique de la litterature et sur le jugement argumente d’experts cliniciens au sein d’un groupe de travail multidisciplinaire. Avant publication, les recommandations sont revues par des experts cliniciens independants du groupe de travail. Resultats cet article presente les recommandations nationales relatives aux traitements locoregionaux des metastases pulmonaires, osseuses, cutanees, hepatiques et digestives chez des patients atteints d’un melanome cutane pauci-metastatique.
Published: 2014
Full Text: View/download PDF

44. Endoscopic 3rd ventriculocisternostomy: Procedural complications and long-term dysfunctions?

Author: Stéphane Derrey, A. Borden, Pierre Fréger, A. Melot, Emmanuel Gerardin, S. Curey-Lévêque, and François Proust
Subjects: Adult, Male, medicine.medical_specialty, Multivariate analysis, Adolescent, Time, Ventriculostomy, Central nervous system disease, Young Adult, Postoperative Complications, medicine, Humans, Child, Aged, Retrospective Studies, Aged, 80 and over, medicine.diagnostic_test, business.industry, Endoscopic third ventriculostomy, Infant, Endoscopy, Retrospective cohort study, Middle Aged, medicine.disease, Surgery, Hydrocephalus, Treatment Outcome, Child, Preschool, Etiology, Female, Neurology (clinical), business, Complication
Abstract: Background and purpose The endoscopic third ventriculostomy (ETV) has become the treatment of choice for managing non-communicating hydrocephalus. The aim of this study was to evaluate the efficacy and the morbi-mortality of this procedure and its long-term outcome. Patients and methods This retrospective study involved 82 consecutive patients treated for non-communicating hydrocephalus by ETV, in a single centre, between June 1999 and November 2008. The main criterion of efficacy was clinical improvement with shunt independence. The secondary criteria were the ventricular size (third and lateral ventricles) outcome and the procedural morbidity and mortality. In order to determine the predictive factors of dysfunction, a uni- and multivariate analysis was conducted. Results Divided in two groups, the overall success rate was 65.4% in the paediatric group ( n = 26) and 83.9% in the adult group ( n = 56), after respectively a mean follow-up of 59.1 ± 36.7 and 49.3 ± 27.7 months. A procedural complication occurred in 5 patients (6.1%), with no procedure-related death. The predictive factors of ETV failure were an infectious aetiology and an age less than 16. Changes in ventricular size and success rate were independent. Conclusions ETV is an effective procedure at long-term for the management of non-communicating hydrocephalus with low morbidity. Therefore, it should be considered as first-line treatment. Cerebrospinal meningitis infection and young age both expose patients to possible dysfunction.
Published: 2013
Full Text: View/download PDF

45. Distal middle cerebral artery aneurysm: A proposition of microsurgical management

Author: Emmanuel Gerardin, Pierre Fréger, O. Langlois, S. Curey, T Calvacante, Stéphane Derrey, François Proust, and Hélène Castel
Subjects: Adult, Male, Microsurgery, Middle Cerebral Artery, medicine.medical_specialty, Subarachnoid hemorrhage, Adolescent, Aneurysm, Ruptured, Neurosurgical Procedures, Brain Ischemia, Young Adult, Aneurysm, Risk Factors, Modified Rankin Scale, medicine.artery, medicine, Humans, Longitudinal Studies, cardiovascular diseases, Child, Aged, Retrospective Studies, Epilepsy, business.industry, Angiography, Digital Subtraction, Intracranial Aneurysm, Retrospective cohort study, Middle Aged, Subarachnoid Hemorrhage, Prognosis, medicine.disease, Surgery, Hydrocephalus, Treatment Outcome, Relative risk, Anesthesia, Middle cerebral artery, Cohort, Disease Progression, Female, Neurology (clinical), Nervous System Diseases, Tomography, X-Ray Computed, business
Abstract: Objectives Based on a cohort of patients treated on distal middle cerebral artery (MCA) aneurysm by microsurgical approach, the objectives were to assess the following: the postoperative functional outcome, study the causes of early neurological deterioration and to determine the predictive factors of favourable outcome. Patients and methods From a neurovascular prospective database, this retrospective longitudinal study included all the patients treated for cerebral aneurysm located on the distal segment of the MCA over two decades (January 1990–December 2011). The patients were all treated by microsurgical clipping exclusion. Any aneurysm was associated to infectious angiopathy. Data were retrieved from the patient's medical charts. The outcome was analysed twice: during the immediate postoperative period and at 6 months according to the modified Rankin scale. The relative risk was estimated for each variable and the prognostic factors were assessed using a multivariate logistic regression model (P Results Twenty-eight patients, mean age 40 ± 13.3 years (median: 43 years; range 6–70 years) were divided into the ruptured group (n = 20) and unruptured group (n = 8). In the ruptured group, the initial clinical status was good (WFNS I–III) in 12 patients (60%) and poor in eight (40%) with an intracerebral haematoma (ICH) in 11 (55%). For both groups, the aneurysm location on the distal MCA decreased at a rate from 64.8% of the insular segment to 25% of the opercular then 10.7% to the cortical. During the hospital stay, neurological deterioration occurred in 16 patients (57.2%). The diagnosed causes were cerebral ischaemia in 10 (35.6%), initial ICH in three (10.7%), hydrocephalus in two (7.1%) and epilepsy in one (7.1%). At 6 months, a favourable outcome (mRS 0–2) was observed in 19 patients (68.1%), a definitive morbidity in seven (24.9%) and death in two (7.2%). Based on the prognostic factors, only the absence of immediate postoperative neurological deterioration was identified as significant for a favourable outcome. Conclusion These rare cerebral aneurysms resulted in a high proportion of poor initial status related to a frequent ICH. Cerebral ischaemia was a major cause of the immediate neurological deterioration and the absence of immediate neurological deterioration was the single identified prognostic factor.
Published: 2013
Full Text: View/download PDF

46. Lumbar spinal stenosis: Which predictive factors of favorable functional results after decompressive laminectomy?

Author: P. Chassagne, Pierre Fréger, François Proust, Stéphane Derrey, A.-C. Tobenas, M. Ould Slimane, Franck Dujardin, S. Leveque, and E. Foulongne
Subjects: Male, Multivariate analysis, Cauda Equina, Decompressive laminectomy, medicine.medical_treatment, Comorbidity, Severity of Illness Index, Spinal Stenosis, Risk Factors, Prospective Studies, Prospective cohort study, Sténose du canal rachidien lombaire, Résultat fonctionnel à long terme, Univariate analysis, education.field_of_study, Lumbar Vertebrae, Laminectomy, Lumbar spinal stenosis, Cauda equina, Middle Aged, Decompression, Surgical, Treatment Outcome, medicine.anatomical_structure, Female, Spinal Nerve Roots, Long-term functional outcome, medicine.medical_specialty, Population, Clinical Neurology, medicine, Humans, Obesity, Mobility Limitation, education, Aged, Facteur prédictif, business.industry, Nerve Compression Syndromes, Recovery of Function, Intermittent Claudication, medicine.disease, Surgery, Laminectomie, Neurology (clinical), Predictive factor, business, Low Back Pain, Follow-Up Studies
Abstract: Background and purpose Long-term results of decompressive laminectomy in degenerative lumbar stenosis have been studied in only six prospective studies. The objective of our study was to evaluate the functional outcome at long term of patients after decompressive laminectomy in lumbar stenosis and to determine predictive factors of favorable outcome. Methods A prospective cohort data were collected by an independent observer five years after decompressive laminectomy for degenerative lumbar stenosis. The endpoint was the assessment of the Beaujon score for functional evaluation. The result was considered as favorable if the Beaujon score increased by at last five points between the preoperative stage and at follow-up examination. Logistic regression was then performed with univariate and multivariate analysis to reveal predictive factors of good long-term outcome ( P ≤ 0.05). Results The preoperative characteristic of our population ( n = 98) was a mean age of 67.3 ± 8.8 years, a low comorbidity (mean Charlson score = 2.8 ± 1.5), overweight status (BMI = 29.4 ± 6.3) and the mean Beaujon score was 9.3 ± 3.1. At five years after surgery, the mean Beaujon score became 14.1 ± 4.2. Favorable functional outcome concerned 45.9% of our series. The predictive factor of favorable outcome identified in the univariate analysis the neurological deficit ( P = 0.05) and in the multivariate analysis the low comorbidity ( P = 0.01). Conclusion The long-term results of surgical treatment of lumbar spinal stenosis were moderate with an improved outcome in 49.5% of cases in our study. The only independent factor to a favorable outcome was the low comorbidity.
Published: 2013
Full Text: View/download PDF

47. Effects of melatonin in the treatment of asthenia in aneurysmal subarachnoid hemorrhage

Author: O. Langlois, Stéphane Derrey, François Proust, S. Curey, François-Xavier Ferracci, Vianney Gilard, Service de neurochirurgie [CHU Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), and Normandie Université (NU)-Normandie Université (NU)
Subjects: Adult, Male, medicine.medical_specialty, Subarachnoid hemorrhage, Population, Context (language use), Aneurysm, Ruptured, 030204 cardiovascular system & hematology, Melatonin, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Clinical endpoint, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Vasospasm, Intracranial, Prospective Studies, education, Prospective cohort study, Depression (differential diagnoses), Aged, education.field_of_study, business.industry, Middle Aged, medicine.disease, Intracranial aneurysm, 3. Good health, Treatment Outcome, Anesthesia, Asthenia, Cohort, Female, Surgery, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug
Abstract: Background and objectives Survivors of aneurysmal subarachnoid hemorrhage (aSAH) commonly experience sleep disorders resulting in asthenia. The objective of this prospective study was to determine, in a cohort of patients with treated ruptured intracranial aneurysm (IA), the proportion of asthenia at 2 months, in a cohort of patients treated with melatonin and in a control cohort. Patients and methods Twenty consecutive patients admitted for the treatment of ruptured IA and able to answer a standardized questionnaire were included in the study. After evaluation for fatigue at discharge, we divided our population into 2 cohorts of 10 patients: the first cohort was treated with melatonin for a period of 2 months; the second cohort had no specific treatment for fatigue. The primary endpoint was the proportion of asthenia at 2 months in both groups. Confounding factors, such as depression, autonomy and apathy were evaluated at the same time. Results At discharge, there was no significant difference observed between both groups in terms of mean age and initial clinical status (WFNS, Rankin Scale and Fatigue Severity Scale). At 2 months, the mean FSS score in the control group was of 4.7 ± 1.0 versus 3.8 ± 0.9 in the melatonin group ( P = 0.03). The mean MADRS score in the control group was of 1.1 ± 1.45 versus 2.7 ± 2.5 in the melatonin group ( P = 0.10). The mean LARS score in the control group was of –32.5 ± 1.7 versus –31.7 ± 1.9 in the melatonin group ( P = 0.24). Discussion In a prospective evaluation of post-aSAH fatigue, we suggest that melatonin could decrease fatigue. There is no significant impact on depression and apathy. Further studies would be necessary to improve our comprehension of fatigue physiopathology in a context of aSAH.
Published: 2016
Full Text: View/download PDF

48. Occipital nerve stimulation improves the quality of life in medically-intractable chronic cluster headache: Results of an observational prospective study

Author: Caroline Roos, Sylvie Romettino, Jean Régis, Serge Blond, Stéphane Derrey, Stephan Chabardes, Coralie Roger, Christian Lucas, Béchir Jarraya, Evelyne Guegan-Massardier, Sophie Colnat-Coulbois, Dominique Valade, François Caire, Jocelyne Bloch, Frederic Bourdain, Pierric Giraud, Denys Fontaine, Michel Lanteri-Minet, Anne Donnet, Bich Dang-Vu, Jimmy Voirin, Christèle Creach, Alda Rocca, Service de Neurochirurgie, Centre Hospitalier Universitaire de Nice (CHU Nice), Service de neuro-chirurgie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de neurologie [Lille], Epilepsies, Lesions Cerebrales et Systemes Neuraux de la Cognition, Université de la Méditerranée - Aix-Marseille 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service de neurologie [Rouen], Institut d'Imagerie BioMédicale (I2BM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Department of Neuroradiology, Foch Hospital, Suresnes, France, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Urgence Cephalees, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Deparment of Neurology (LARIBOISIERE - Neurologie), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Neurologie [CHU de Saint-Étienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), [GIN] Grenoble Institut des Neurosciences (GIN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre Hospitalier Annecy-Genevois, 74000-Annecy, France, Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Service de Neurologie [Hôpitaux Civils de Colmar], Hôpitaux Civils Colmar, Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Department of Clinical Neurosciences [CHU Vaudois - Lausanne, Switzerland] (Neurosurgery Service & Gamma Knife Center), Service de Neurochirurgie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Neurochirurgie [CHU Limoges], CHU Limoges, Hôpital Cimiez [Nice] (CHU), Pain Clinic, CHU de Nice, Nice, France, Département d'Evaluation et Traitement de la Douleur, Pôle Neurosciences, Cliniques du Centre Hospitalo-Universitaire de Nice, Hôpital Pasteur, Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de neurologie[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Service de neurologie [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de neurologie [CHU de Saint-Étienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), and Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Adult, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Cluster Headache, Electric Stimulation Therapy, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Quality of life, EQ-5D, Internal medicine, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Young adult, Attack frequency, Prospective cohort study, ComputingMilieux_MISCELLANEOUS, Aged, business.industry, Cluster headache, General Medicine, Middle Aged, medicine.disease, 3. Good health, Surgery, Treatment Outcome, Quality of Life, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Occipital nerve stimulation, Observational study, Female, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract: Background Occipital nerve stimulation (ONS) has been proposed to treat chronic medically-intractable cluster headache (iCCH) in small series of cases without evaluation of its functional and emotional impacts. Methods We report the multidimensional outcome of a large observational study of iCCH patients, treated by ONS within a nationwide multidisciplinary network ( https://clinicaltrials.gov NCT01842763), with a one-year follow-up. Prospective evaluation was performed before surgery, then three and 12 months after. Results One year after ONS, the attack frequency per week was decreased >30% in 64% and >50% in 59% of the 44 patients. Mean (Standard Deviation) weekly attack frequency decreased from 21.5 (16.3) to 10.7 (13.8) ( p = 0.0002). About 70% of the patients responded to ONS, 47.8% being excellent responders. Prophylactic treatments could be decreased in 40% of patients. Functional (HIT-6 and MIDAS scales) and emotional (HAD scale) impacts were significantly improved, as well as the health-related quality of life (EQ-5D). The mean (SD) EQ-5D visual analogic scale score increased from 35.2 (23.6) to 51.9 (25.7) ( p = 0.0037). Surgical minor complications were observed in 33% of the patients. Conclusion ONS significantly reduced the attack frequency per week, as well as the functional and emotional headache impacts in iCCH patients, and dramatically improved the health-related quality of life of responders.
Published: 2016
Full Text: View/download PDF

49. Headache changes prior to aneurysmal rupture: A symptom of unruptured aneurysm?

Author: François Proust, Lou Grangeon, Stéphane Derrey, M. Sallansonnet-Froment, V. Gilard, David Maltête, Evelyne Guegan-Massardier, Service de neurochirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de neurologie [Rouen], Normandie Université (NU)-Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and UNIROUEN - UFR Santé (UNIROUEN UFR Santé)
Subjects: Adult, Male, Pediatrics, medicine.medical_specialty, Sentinel headache, Aneurysm, Ruptured, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Lumbar, Aneurysm, Surveys and Questionnaires, medicine, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Cerebral aneurysm, Thunderclap headaches, Aged, Retrospective Studies, medicine.diagnostic_test, business.industry, Case-control study, Headache, Retrospective cohort study, Intracranial Aneurysm, Middle Aged, medicine.disease, Thunderclap headache, Surgery, Cerebral Angiography, Case-Control Studies, Cohort, Chronic headache, Female, Neurology (clinical), Headaches, medicine.symptom, business, 030217 neurology & neurosurgery, Cerebral angiography
Abstract: International audience; BACKGROUND AND OBJECTIVES:The symptomatic status of unruptured aneurysms has to be looked for. The objective of this retrospective case-control study was to identify the headache semiologic characteristics of symptomatic aneurysms during the 3 months prior to patient admission.PATIENTS AND METHODS:The case cohort was composed of 40 consecutive patients admitted for the treatment of a ruptured intracranial aneurysm (IA) and able to answer a standardized questionnaire by the same neurologist. This cohort was matched with a control cohort of 40 patients operated on for a degenerative lumbar pathology. This questionnaire, using the criteria for headache characteristics according to the International Headache Society (IHS) enabled us to classify headaches during the previous 3 months prior to the rupture (study period) and during the year prior to the period studied (reference period) in both cohorts. Headache status was considered as unstable if there were modifications of semiologic headache characteristics, thunderclap headaches or de novo headaches, or on the contrary stable.RESULTS:During the status period, chronic headaches were reported by 31 patients (77.5%) in the studied cohort and 35 (87.5%) in the control cohort. During the study period, the cephalagia status was stable in 19 patients (47.5%) versus 35 patients (87.5%) in the control cohort (P
Published: 2016
Full Text: View/download PDF

50. Delayed intracranial hematoma following stereoelectroencephalography for intractable epilepsy

Author: Pierre Fréger, Marie Gilles Baray, Dominique Parain, Stéphane Derrey, François Proust, Axel Lebas, and Christophe Marguet
Subjects: Male, Decompressive Craniectomy, medicine.medical_specialty, Time Factors, Epilepsy, Frontal Lobe, Intracranial hematoma, medicine.medical_treatment, Drug Resistance, Stereoelectroencephalography, Brain Ischemia, Stereotaxic Techniques, Pseudoaneurysm, Fatal Outcome, Hematoma, medicine, Humans, Epilepsy surgery, Postoperative Period, Child, Cerebral Hemorrhage, business.industry, Electroencephalography, General Medicine, medicine.disease, Magnetic Resonance Imaging, Electrodes, Implanted, Surgery, Hematoma, Subdural, Withholding Treatment, Stereotaxic technique, Anticonvulsants, Interdisciplinary Communication, Decompressive craniectomy, Epileptic seizure, Intracranial Hypertension, medicine.symptom, Tomography, X-Ray Computed, business
Abstract: Intracranial bleeding following stereoelectroencephalography (sEEG) is rare and commonly occurs early after electrode implantation. The authors report the case of a delayed intracranial hematoma following sEEG. This 10-year-old boy was referred to the authors' department to undergo an sEEG study for intractable epilepsy, with the hypothesis of a single localized epileptic zone in the left precentral region. To perform the exploration, 14 depth electrodes were implanted under stereotactic conditions. The results of a postoperative CT scan performed routinely at the end of the surgical procedure were normal. Eight days later, following an epileptic seizure, the child's condition worsened. The neurological examination revealed a left hemiparesis, agitation, and coma due to a right subdural hematoma with intraparenchymal bleeding. Despite a surgical evacuation followed by a decompressive craniectomy, the curative treatments were stopped 1 week later due to severe diffuse ischemic lesions found on MRI studies. This is the first observation of a delayed hematoma following an sEEG procedure. The mechanism underlying this complication remains unclear, but the rupture of a growing pseudoaneurysm caused by the electrode's implantation or the tearing of a neighboring vessel by an electrode were suspected. In consequence, physicians must remain vigilant during the entire sEEG recording period and probably also several days after electrode removal.
Published: 2012
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

139 results on '"Stéphane Derrey"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources